CV

Curriculum Vitae for Michael Hecht Olsen


Side 1: Indholdsfortegnelse

Side 2: Indledning

Side 3-6: Min egen uddannelse
Eksaminer og lignende (side 3)
Ansættelser (side 3-4)
Kurser (side 4-5)
Kongresser (side 5)
Specifik kardiologisk erfaring (side 6)

Side 6-15: Undervisningserfaring
Kurser og uddannelsesorienterede møder (side 7-9)
(lægfolk, prægraduat, postgraduat)
Foredrag (side 10-13)
(lægfolk, prægraduat, postgraduat)
Vejledning (side 14-16)
Editor (side 17)
Reviewer (side 17)

Side 18-21: Erfaring som koordinator
Diverse (side 18)
Internationale samarbejdspartnere (side 19)
Æresbevisninger, legater og anden økonomisk støtte (side 20-21)

Side 21-47 Publikationer
Kapitler i bøger (side 21)
Andre Publikationer (side 22)
Artikler nationalt (side 23)
Artikler internationalt (side 24-34)
Abstrakter internationalt (side 35-47)

Indledning

Af vedlagte fremgår at jeg har erfaring inden for alle syv kompentence-områder:
1) Medicinsk ekspert: Jeg har haft relevante stillinger og kurser
2) Kommunikator: Jeg underviser og vejleder på flere faglige niveauer. Desuden kommunikerer jeg godt med patienterne og bliver ofte benyttet til den vanskelige samtale.
3) Samarbejder: Jeg samarbejder godt med såvel kolleger som andre faggrupper og fungerer godt i behandler-teamet på afdelingen
4) Administrator: Jeg er bestyrrelsesmedlem både i Dansk Hypertensions Selskab og i European Society of Hypertension og har desuden administrativ erfaring som forskningskoordinator i Den Kardiovaskulære Forskningsenhed, Medicinsk Afd. M, Glostrup Hospital og som tidligere vagtplanlægger
5) Sundhedsfremmer: Jeg har arbejdet som sundhedsfremmer dels i egenskab af bestyrelsesmedlem i Dansk Hypertensions Selskab og European Society of Hypertension og dels ved undervisning af lægfolk gennem Hjernesagen og Apoteker Foreningen
6) Akademiker: Jeg har stor personlig forskningsaktivitet med internationale samarbejdspartnere og har været og er fortsat ph.d. vejleder
7) Professionel: Jeg tilslutter mig god klinisk praksis og holder mig opdateret gennem kurser og litteratur


Min egen uddannelse (side 3-6) (medicinsk ekspert)

Eksaminer og lignende

1985: Matematisk-fysisk studentereksamen, Niels Steensens Gymnasium

1987: Afløsningsopgave i anatomi, Københavns Universitet: Det aksiale skelets funktionelle anatomi

1992: Lægevidenskabelige embedseksamen, Gennemsnit 11.1, Københavns Universitet

1996-99: Ph.d. studerende, Lægevidenskabelige Fakultet, Københavns Universitet

1999: Erhvervelse af Ph.d. grad, Københavns Universitet:
”Vaskulær sammenhæng mellem hypertension og insulin resistens”

2001: Tilladelse til selvstændigt virke

2007: Speciallæge i kardiologi 1. april 2007

2009: Forsvar af doktordisputats 20/11-09: “New Cardiovascular Risk
Markers - Do They Improve Risk Prediction and Influence Treatment Indication and Choice?”

Ansættelser

1992-93: Værnepligt ved Forsvaret 11 mdr.

1993: Reservelæge, Medicinsk Endokrinolo¬gisk afd. F, KAS Herlev 2 mdr.

1993-94: Turnus, Kirurgisk Gastroen¬terologisk afd. D, KAS Herlev 6 mdr.

1994: Turnus, Medicinsk Endokri¬no¬logisk afd. F, KAS Herlev 6 mdr.

1994-95: Praksisreservelægetid, lægerne Munch-Fals, Gentofte 6 mdr.

1995: Reservelæge, Medicinsk afd. C, KAS Glostrup 6 mdr.

1995: Klinisk assistent, Medicinsk afd. C, KAS Glostrup 4 mdr.

1996-99: Klinisk assistent, Klinisk Fysiologisk og
Nuklearmedicinsk Afd., KAS Glostrup 48 mdr.

2000: Introduktionsstilling 13317i i intern medicin,
Medicinsk afd. M, KAS Glostrup 12 mdr.

2001: Introduktionsstilling 11639i i intern medicin,
Klinik Y, Medicinsk Center, Bispebjerg Hospital 8 mdr.

2001-02: Kursusstilling i intern medicin 9829354-2-13-03,
Klinik Y, Medicinsk Center, Bispebjerg Hospital 12 mdr.

2002-03: Kursusstilling i intern medicin 9829354-2-13-03,
Reumatologisk Afdeling, Frederiksberg Hospital 6 mdr.

2003: Kursusstilling i intern medicin 9829354-2-13-03,
Klinik G, Medicinsk Center, Bispebjerg Hospital 6 mdr.

2003: 1. reservelæge vikariat,
Klinik Y, Medicinsk Center, Bispebjerg Hospital 1 mdr.

2003: Et-årig 1. reservelæge stilling i kardiologi, start 1. oktober,
Medicinsk afdeling B, Hillerød Centralsygehus 12 mdr.

2004: Tre-årig 1. reservelæge stilling i kardiologi, start 1. oktober,
Kardiologisk afdeling B, Rigshospitalet 36 mdr.

2007: Overlæge stilling i kardiologi med 50 % forskning, 46 mdr.
start 1. oktober, Medicinsk afdeling M, Glostrup Hospital

2008-: Ekstern klinisk Lektor ved Københavns Universitet

2011 Feb: Klinisk lektor ved Syddansk Universitet 6 mdr.

2011 Aug-: Klinisk professor i Hypertension ved Syddansk Universitet

2011 Aug-: Overlæge stilling i hypertension ved Endokrinologisk Afd. M,
Odense Universitetshospital

2011 Aug-: Ekstern klinisk lektor ved Københavns Universitet

2012 April: Æresprofessor ved Hypertension in Africa Research Team (HART)
School for Physiology, Nutrition and Consumer Sciences, North-West University, Potchefstroom, South Africa

Kurser

1992: Forsvarets pædagogiske kursus
1996: Kursus i ekkokardiografi på Rigshospitalet, Kardiologisk afd. B, Jens Rokkedal, Frank Stensgaard, Ulrik Abildgaard og Per Hildebrandt.
1996: A course in the use of myographs to determine structure and function of isolated small arteries, M. J. Mulvany, Farmakologisk Institut, Århus.
1996: Vascular remodeling and contraction in health and disease ved M. J. Mulvany, European Heart House, Nice, Frankrig.
1997: Skriftlig udformning af videnskabelige arbejder, Ib Severin, Panum.
1997: Basic statistics for medical researchers, Lene Theil Skovgaard.
1997: Analysis of variance and regression, Lene Theil Skovgaard.
1997: Components of variance and observer variation, Lene Theil Skovgaard.
1998: Diabetes research. Methodology in theory and in practice, Bo Feldt-Rasmussen og Ulla Feldt-Rasmussen, Medicinsk Afd. P, Rigshospitalet.
1998: Kursus i Doppler-ultralyd, Torben Lorentsen og Christian Nolsøe, Ultralyd afd., KAS Herlev.
2000: Kardiovaskulær farmakologi I. Fællesudvalget. 12 timer
2000: Hjerteinsulfficiens. Fællesudvalget. 12 timer
2000: Sandbjerg meeting on cardiovascular function and ion transport på Sandbjerg Gods. Ved Christian Aalkjær og Holger Nilsson.
2000: Brystsmerter. Fællesudvalget. 6 timer
2000: Tromboemboli. Fællesudvalget. 12 timer
2001: Kardiovaskulær farmakologi II. Fællesudvalget. 12 timer
2001: Intensiv beandling. Fællesudvalget. 12 timer
2001: Kardiovaskulær farmakologi III. Fællesudvalget. 12 timer
2001: Avanceret ekkokardiografi. DCS, KAS Gentofte. 6 timer
2001: Pacemaker kursus, Niels Gadsbøl, Bispebjerg Hospital. 18 timer
2002: Ekkokardiografi 2, DCS, KAS Gentofte. 12 timer
2002-03: Aztecc kommunikationskursus, Aztra Zenica,
(3 dele 2-3 dages varighed) 8 dage
2001: Akut Medicin, A-kursus, København 5 dage
2001: Kardiologi, A-kursus, Skejby Sygehus 5 dage
2002: SOSA, A-kursus, Næstved 4 dage
2002: Infektionsmedicin, A-kursus, Hvidovre Hospital 5 dage
2002: Klinisk Farmakologi, A-kursus, Næstved 5 dage
2003: Endokrinologi, A-kursus, Herlev Amtssygehus 5 dage
2003: Nephrologi, A-kursus, Rigshospitalet 4 dage
2003: Lungemedicin, A-kursus, København 5 dage
2005 TEE kursus, DCS 2 dage
2005 Arytmi kursus, DCS 2 dage
2005 State of the art, DCS 3 dage
2007 Rigshospitalets vejlederkursus 2-3 dage
2010 OLAU modul 1 5 dage

Kongresser

American College of Cardiology Meeting 1999, 2001, 2003, 2004, 2005, 2006
American Society of Hypertension Meeting 1999, 2002
American Heart Association Meeting 1999, 2002, 2004
European Society of Cardiology Meeting 2003, 2004, 2005, 2006, 2008, 2014
European Society of Hypertension 2000, 2003, 2007, 2008, 2009, 2010, 2011, 2012, 2013
EuroPrevent 2010
International and European Society of Hypertension Meeting 2002, 2008, 2014
World Congress of Cardiology 2002


Specifik kardiologisk erfaring

Jeg har stor erfaring inden for transthorakal såvel som transøsophagal ekkokardiografi

Jeg kan selvstændigt foretage og tolke KAG (>150 procedure)

Jeg kan anlægge temporær paceelektrode



Undervisningserfaring (Side 6-14) (kommunikator, sundhedsfremmer)

Kurser og uddannelsesorienterede møder:

Lægfolk

2002-08 Hypertension, medicinske konsulenter, MSD

2007 Hypertension, Farmaceutisk efteruddannelse, Pharmakon

2008-09 Sygeplejersker, Medicinsk Afdelig M, Glostrup Hospital

2010 Hypertension og dyslipidæmi, Apotekere i Nordsjælland, MSD

2010 Det metaboliske Syndrom, et dags bioanalytikersymposium, Medinor

Prægraduat

2008-09 Klinisk undervisning af 7.-semester medicinstuderende på Medicinsk Afdeling M, Glostrup Hospital

Postgraduat

2001-02 Akut Kardiologi, Yngre læger, Klinik Y, Bispebjerg Hospital

2003 Clinical intervention in the RAAS: ACE inhibitors, AT1 blockers, Aldosterone inhibitors. Del af tredags ph.d.-kursus: Cardio-renal endocrinology: The Renin-Angiotensin-Aldosterone System. Ledet af Ole Skøtt, Medicinsk Biologisk Institut, Odense Universitet.

2006 Clinical intervention in the RAAS: ACE inhibitors, AT1 blockers, Aldosterone and Renin inhibitors. Del af ph.d.-kursus ledet af Ole Skøtt, Medicinsk Biologisk Institut, Odense Universitet. Cardio-renal endocrinology: The Renin-Angiotensin-Aldosterone System.

2006 Postgraduat kursus – fra forskning til klinik under Dansk Hypertensions Selskab (medarrangør og underviser)

2007 Ph.d. kursus: Prevention af kardiovaskulære sygdomme, epidemiologiske og kliniske eksperimentelle metoder

2007 Fællesmøde for Dansk Hypertensionsselskab og Dansk Cardiologisk Selskab: Hypertension, metabolisk syndrom og myocardieinfarkt. (medarrangør).

2007 Postgraduat kursus – fra forskning til klinik under Dansk Hypertensions Selskab (medarrangør). Farmakologisk Institut, Århus Universitet.

2006 European Society of Hypertension 2007 Educational Master Course on Hypertension and Cardiovascular Risk. Budapest May 9th 2007.

2007 Organ damage in hypertension. Left ventricular hypertrophy - Role of ECG. Teaching sessions European Society of Hypertension Meeting, Milano, Italy

2007 European Society of Hypertension 2007 Educational Master Course on Hypertension and Cardiovascular Risk. Riga October 19th 2007.

2007 Postgraduat kursus – fra forskning til klinik under Dansk Hypertensions Selskab (medarrangør). Medicinsk Biologisk Institut, Odense Universitet.

2008 Dansk Hypertensionsselskabs Vintermøde om European Society of Hypertension Guidelines 2007 (medarrangør). København.

2008 Dansk Hypertensionsselskabs Efterårsmøde: Late puzzling trials in hypertension: implications for medical practice in Denmark? (medarrangør). Odense Universitets Hospital.

2008 Fælles forskningsmøde for Medicinsk afdeling M, Tværfaglig Funktionsdiagsnostisk afdeling og Klinisk Fysiologisk/Nuklearmedicinsk afdeling Glostrup Hospital (Hovedarrangør). Glostrup.

2008 European Society of Hypertension 2008 Educational Master Course on Hypertension and Cardiovascular Risk. Copenhagen November 21-22th 2008.

2008 DCS efterårsmøde 2008. Hypertension. ”State of the art behandling 2008”

2009 Afdelingsmøde Medicinsk afdeling M, Glostrup Hospital: Klinik,
forskning og uddannelse (Arrangør). Glostrup, Januar

2009 Subklinisk kardiovaskulær skade. Patofysiologiske – kliniske - behandlingsmæssige aspekter. DHS Årsmøde i Christiansminde (Arrangør).


2009 Hypertension and cardiovascular (CV) ageing – Bridging basic research
and clinical science. Nordisk ph.d. internatkursus sponsoreret af The joint Committee of the Nordic Medical Research Councils (NOS-M) og DaCRA (Arrangør og kursusleder). Lyngby, Maj

2009 Inflammatory markers in Hypertension. Breakfast workshop in Milan at
ESH Congres 2009 (Arrangør).

2010 Inflammation, hypertension og atherosklerose. DHS eftermiddagsmøde i København (Arrangør).

2010 Fremtidens Blodtryksmåling. Hvordan? –Hvor? – Hvornår? DHS Årsmøde i Korsør (Arrangør).

2010 Hypertension and Cardiovascular Disease - Bridging basic research, clinical science and daily practice. The Second Nordic University Research Course, Oslo, June 17-18. Nordisk ph.d. internatkursus sponsoreret af DaCRA (Arrangør og kursusleder)

2010 Albuminuria is associated with high cardiovascular risk even within the definition of microalbuminuria. Topical workshop in Oslo at ESH 2010 congres (Arrangør).

2010 Measurement of subclinical organ damage in daily practice.Topical workshop in Oslo at ESH 2010 congres (Arrangør).

2010 Measuring subclinical cardiovascular damage is not feasible in the daily clinic. What can we do? Breakfast workshop in Oslo at ESH 2010 congress. (Arrangør).

2011 How does target organ damage change the risk in hypertension? Breakfast workshop in Milano at ESH 2011 congress.

2011 Obesity and other risk factors. Teaching session in Milano at ESH 2011 congress.

2011 The Renin-Angiontensin-Aldosterone System and Cardiovascular disease. En ud af tre dage ved Ph.d. kursus, Institut for medicinsk biology, fysiologi og farmakologi, Syddansk Universitet (medarrangør)

2012 The relationship between hypertertension, atherosclerosis and cardiovascular events. Indlæg ved Ph.d. kursus Atherosclerosis – from molecular mechanisms to clinical disease ved Klinisk Institut, Århus Universitet, Skejby

2012 Hypertension and Metabolic Syndrome. Indlæg ved Ph.d. kursus Basal Metabolism and Molecular Mechanisms in the Metabolic Syndrome ved Endokrinologisk Forskningsenhed, OUH

2012 Medarrangør af the Third Nordic University Research Course, Ystad/Malmö, September 10-12. Give tre indlæg: Risk assessment and preventive strategies. Does ambulatory blood pressure measurements predict outcome independently of subclinical organ damage? The Prognostic Shift from Diastolic to Systolic Blood Pressure in the MORGAM Project.

2012 Arrangør af Ph.d. kursus: Hypertension and target organ damage – how to do, OUH, November 20-21. Give to indlæg: Flow mediated vasodilatation in the brachial artery og Echocardiografic left atrium size and –function.

2013 Danska befolkningsstudier som bas för riskstratifiering Kardiovaskulär epidemiologi i bred belysning – från befolkning till individ och prevention. Indlæg ved Symposium 21 marts 2013 på Skånes Universitetssjukehus Malmö: Kardiovaskulär epidemiologi igår, idag og imorgen.

2013 Arrangør af Ph.d. kursus: Controversis and new discoveries within hypertension. Give indlæg: Blood pressure goals -
"The lower the better” or ”The J-curve”. Korsør, April 19-20, 2013.

2013 Arrangør af symposium: Optimeret Diabetes Behandling -
Hypoglykæmi og Hypertension. Indlæg om hypertensions-behandling. Esbjerg, May 14, 2013.

2013 Hypertension and Metabolic Syndrome. Indlæg ved Ph.d. kursus Basal Metabolism and Molecular Mechanisms in the Metabolic Syndrome ved Endokrinologisk Forskningsenhed, Nyborg, May 24, 2013.

2013 Behandling af Hypertension hos Ældre Patienter. Indlæg ved DCS kursus: Den ældre kardiologiske patient. Nyborg, June 12, 2013.

2013 The Renin-Angiontensin-Aldosterone System and Cardiovascular disease. En ud af tre dage ved Ph.d. kursus, Institut for medicinsk biology, fysiologi og farmakologi, Syddansk Universitet (medarrangør)

2013 Arrangør af workshop: Workshop in Artery Disease. From basic biological research, through better pathophysiological understanding, to improved (individualized) prevention and treatment. OUH, November 26, 2013

2013 Arrangør af symposium: Symposium in honour of Stéphane Laurent
Different aspects of large artery disease. OUH, November 26, 2013

2013 Hypertension – Number one killer in the world. Indlæg ved DCS kursus for hoveduddannelseslæger i Præventiv kardiologi og rehabilitering. OUH, December 4, 2013

2014 Arrangør af Nordisk Ph.d. internatkursus ved SDU: “Artery disease – From basic biological research through better understanding to improved prevention and treatment”. Nyborg, april 7-10, 2014

2014 High and Low Blood Pressure. CV risk, BP goals, Antihypertensive Treatment. Indlæg ved Ph.d. kursus “Cardiovascular function and methods”. Århus Universitet, November 13, 2014

2014 Hypertension – Number one killer in the world. Indlæg ved DCS kursus for hoveduddannelseslæger i Præventiv kardiologi og rehabilitering. Bispebjerg Hospital, December 3, 2014.

Foredrag

Lægfolk

2004 Behandling af Forhøjet Blodtryk –En Effektiv Forebyggelse af Apoplexi (Slagtilfælde). 3 foredrag i henholdsvis Glostrup, Hvidovre og København for Hjernesagen i anledning af deres 10 års jubilæum.

2011 Livstilssygdomme – Forhøjet blodtryk. Folkeuniversitetet i Odense

Postgraduat

1995 Vaskulære forandringer og insulinresistens ved hypertension.
Staff-meeting, Glostrup Amtssygehus.

1996 Sammenhæng mellem vaskulære og kardielle forandringer ved essentiel hypertension. Yngre Kardiologers årsmøde, Skejby og Herlev Sygehus.

1998 Vigtigheden af vaskulær hypertrofi for udvikling af insulinresistens hos patienter med hypertension – metodologiske overvejelser ved brug af euglukæmisk klamp teknik til bestemmelse af insulinfølsomhed. Center for Blodtryksforskning, Panum Instituttet.

1998 Brug af flow-medieret vasodilatation som indikator for kardiovaskulær skade. LIFE investigator-møde, Korsør.

1998 Brug af flow-medieret vasodilatation som indikator for kardiovaskulær skade. Staff-meeting, Glostrup Amtssygehus.

1998 Betydningen af koronare karforandringer for koronar flowreserve ved hypertension. Klinisk Fysiologisk/Nuklearmedicinsk Selskabs Årsmøde.

1999 Relation mellem systemiske karforandringer og koronar flowreserve. Astras Cardiovaskulære Årsmøde.

1999 Har patienter med hypertension endotheldysfunktion? LIFE investigator-møde i København.

1999 Er kardiovaskulære forandringer ved længerevarende hypertension udelukkende blodtryksafhængige? Staff-meeting, Glostrup Amtssygehus.

1999 Endotheldysfunktion hos patienter med hypertension. Staff-meeting, Glostrup Amtssygehus.

1999 Is endothelial dysfunction associated with hypertension? A LIFE substudy. Klinisk Fysiologisk og Nuklearmedicinsk Selskabs Årsmøde.

1999 Are cardiac and vascular changes in hypertension only blood pressure dependent? Meeting of the Danish Society of Cardiology and Danish Society of Clinical Physiology and Nuclear Medicine, Rigshospitalet.

2000 En vaskulær sammenhæng mellem hypertension og insulin resistens. LIFE-investigator møde, Kolding.

2000 Hypertensive kardiovaskulære forandringer og betydningen af disse for den insulin-medierede glukoseoptagelse, Center for Blodtryksforskning, Panum Instituttet.

2002 Fra detaile til helhed. LIFE-investigator møde, København.

2002 Er kollagen omsætning relateret til blodtryk eller kardiovaskulær hypertrofi. Temadag om forskning & udvikling, Glostrup Amtssygehus.

2002 Collagen Synthesis is Related to Blood Pressure Rather than Left Ventricular Mass. A LIFE Substudy. World Congress of Cardiology, Sydney, Australia.

2002 Sub-acute Changes in Circulating Collagen Markers During Anti-Hypertensive Treatment. A LIFE Substudy. World Congress of Cardiology, Sydney, Australia.

2002 Dynamics of Collagen Synthesis in Hypertension - Blood Pressure or Treatment Dependent. A LIFE Substudy. International and European Societies of Hypertension Meeting, Praque, Tjekkiet.

2002 Effekt af losartan versus atenolol på insulin følsomhed og perifer vaskulær hypertrofi. ICARUS, et LIFE substudie. Specialistmøde, MSD, København

2002 Effekt af losartan versus atenolol på arteriel hypertrofi. Et LIFE substudie, Dansk Hypertensionsselskab, Frederiksberg Hospital, København.

2003 Effect of losartan versus atenolol on insulin sensitivity and peripheral vascular hypertrophy. ICARUS, a LIFE substudy. LIFE, The science. A Scandinavian specialist meeting, MSD, Oslo, Norge.

2003 Does Aortic Valve Sclerosis add to Cardiovascular Risk independently of Albuminuria in Hypertension? A LIFE Substudy. The American College of Cardiology Meeting, Chicago, USA.

2003 N-terminal proBrain Natriuretic Peptide Predict Cardiovascular Events in Patients with Hypertension and Left Ventricular Hypertrophy. A LIFE Study, Presse-konference, The American College of Cardiology Meeting, Chicago, USA.

2003 Insulin sensitivity and vascular hypertrophy – How are they influenced by treatment? LIFE – Understanding the difference. A Scandinavian specialist meeting, Oslo, Norge.

2003 Hypertensiv organskade. Glostrup Kardiovaskulære Symposium. Glostrup Amtssygehus.

2004 N-terminal pro Brain Natriuretic Peptide Predicts Cardiovascular Events in Patients with Hypertension and Left Ventricular Hypertrophy. A LIFE Study. The American College of Cardiology Meeting, USA.

2004 Does baseline and in-treatment albuminuria predict CV risk and outcome on losartan? Møde for praktiserende læger i Danmark.

2004 N-terminal pro Brain Natriuretic Peptide Predicts Cardiovascular Events
in Patients with Hypertension and Left Ventricular Hypertrophy. A LIFE Substudy. The American College of Cardiology Meeting, USA.

2005 N-terminal pro Brain Natriuretic Peptide Predicts Cardiovascular Events
in Patients with Hypertension and Left Ventricular Hypertrophy. A LIFE Substudy.Møde i netværk for hjertesvigtsklinikker med foredrag om natriuretiske peptiders anvendelse i kardiologien i samarbejde med Dansk Cardiologisk Selskabs arbejdsgruppe for hjertesvigt.

2005 The Effect of Losartan versus Atenolol on Brachial Artery Vasodilatory Capacity and Hypertrophy in Essential Hypertension. A LIFE Substudy. The American College of Cardiology Meeting, USA.

2005 Nye kardiovaskulære risikomarkører – har de andet end videnskabelig betydning? Dansk Hypertensionsselskabs årsmøde 2005.

2005 N-terminal pro brain natriuretic peptide is inversely related to metabolic cardiovascular risk factors – a paradoxical relationship to the metabolic syndrome. The European Society of Cardiology Meeting, Stockholm, Sweden.

2005 N-terminal pro brain natriuretic peptide and urine albumin/creatinine ratio, but not high sensitivity C-reactive protein predicts cardiovascular death in the general population after adjustment for traditional risk factors. The European Society of Cardiology Meeting, Stockholm, Sweden.

2005 Albuminuria, BNP, hsCRP som risikomarkører. Hvad er bedst? – Udsiger de forskellige former for kardiovaskulær risiko? Ved Glostrup kardiovaskulært symposium: Klinisk anvendelse af nogle risikomarkører.

2006 In patients with hypertension and electrocardiographic left ventricular hypertrophy, high hemoglobin was associated with cardiovascular events, low hemoglobin with all-cause mortality, and large fall in hemoglobin with both. The LIFE Study. The American College of Cardiology Meeting, USA.

2006 Albuminuria, Nt-proBNP and hsCRP as risk markers
Which is best? – Do they predict different forms of cardiovascular risk? Del af et større kardiovaskulært symposium i København

Structural and functional vascular changes in hypertension with special emphasis on the carotid arteries. Prediction of cardiovascular complications? – Therapeutical implications. Del af et større kardiovaskulært symposium i København

2007 Hypertension, myokardieinfarkt og hjerteinsufficiens. Fællesmøde for Dansk Hypertensionsselskab og Dansk Cardiologisk Selskab: Hypertension, metabolisk syndrom og myocardieinfarkt

2007 Is the prognostic value of N-terminal pro-brain natriuretic peptide and high sensitivity C-reactive protein independent of subclinical and clinical cardiovascular disease? A LIFE Study. The European Society of Hypertension Meeting, Milano, Italy.

2007 Possible explanations for why losartan- versus atenolol-based antihypertensive treatment reduced cardiovascular events especially well in elderly patients the LIFE study. The European Society of Hypertension Meeting, Milano, Italy.

2007 Afskedssymposium for Hans Ibsen: Nye risikomarkører – Fremtiden eller ”Kejserens nye klæder”?

2008 European Society of Hypertension Guidelines 2007. Møde ved Dansk Hypertensionsselskab: ”Hvilke organskader bør vurderes? – IMT, plaque, UACR, LVMI, EKG m.m.”

2008 Hypertension - ”State of the art behandling 2008” DCS efterårsmøde i Odense.

2010 Role of biomarkers in improving risk assessment models. Invited lecture at EuroPrevent in Praque

2010 Definition and the burden of atrial fibrillation. Invited lecture at The Congress of European Society of Hypertension in Oslo

2012 Invited lecture: A World with 1.56 Billion Hypertensives in 2025
How can we Treat Hypertension in the Future, Joint Session ESH/ESC at the ESH annual congress in London April 2012


Vejledning

2000: Turnus-vejleder, Medicinsk afd. M, KAS Glostrup

2003-07: Ph.d.-vejleder for Marina K. Christensen, ”Kollagen markørers relation til det kardiovaskulære system”, Klinisk Fysiologisk og Nuklear Medicinsk afdeling, KAS Glostrup. Forsvaret og erhvervet september 2007. Bygger på tre artikler, hvoraf de to er skrevet, men ikke indsendt:
1) Christensen MK, Hansen TW, Rasmussen S, Wachtell K, Borch-Johnsen K, Ibsen H, Jensen LT, Jørgensen T, Olsen MH. Are atherosclerotic plaques in the carotid arteries related primarily to hemodynamic or metabolic cardiovascular risk factors?
2) Christensen MK, Hansen TW, Rasmussen S, Ibsen H, Jensen LT, Jørgensen T, Olsen MH. Do atherosclerotic plaques in the carotid arteries predict cardiovascular events independently of traditional cardiovascular risk factors? (skal resubmittes til J Hypertens)

2006: Klinisk vejleder for læger i introduktionsstilling og hoveduddannelse i kardiologi, Kardiologisk afd. B, Hjertecentret, Rigshospitalet

2007-11: Ph.d.-vejleder for Camilla Lund Søraas, ”Den prognostiske betydning af venstre ventrikel hypertrofi efter koronar revaskularisering”, Kardiologisk Afdeling, Ullevaal Universitets Hospital, Oslo med professor Sverre E. Kjeldsen som hovedvejleder. Indleveret 2012.

2008-11: Ph.d.-vejleder for Thomas Sehestedt, ”Betydningen af subklinisk kardiovaskulær skade og nye risikomarkører for risikostratificering specielt hos personer med højt normalt blodtryk”, Medicinsk Afd. M, Glostrup Hospital. Forsvaret og erhvervet 5/2 2011.

2008-13: Ph.d.-vejleder for Stig Lyngbæk, ”SuPAR – en ny markør for udvikling af kardiovaskulær sygdom”, Medicinsk Afd. M, Glostrup Hospital med overlæge Jørgen Jeppesen som hovedvejleder. Forsvaret og erhvervet januar 2013.

2009-14: Ph.d.-hovedvejleder for Julie Vishram, ”Det metaboliske syndroms prognostiske berettigelse og den prognostiske betydning af systolisk versus diastolisk blodtryk ved stigende alder”. Medicinsk Afd. M, Glostrup Hospital og Forskningscenter for Forebyggelse og Sundhed. Indleveret januar 2014.

2009: Bedømmer af Michael Præstholms Ph.d.-opgave ved Århus universitet: “Essential hypertension: vascular and diagnostic aspects with potential influence on patient management” forsvaret 4. december 2009.

2010-14: Ph.d.-vejleder for Kristian Hvidt, ”Blodtryk og central karstivhed hos adipøse børn. Relationer til det metaboliske syndrom og subklinisk kardiovaskulær skade. Effekt af vægtreduktion”. Kardiologisk Afsnit, Medicinsk Afdeling, Holbæk Sygehus.

2011-14: Ph.d.-hovedvejleder for Adam Blyme, “Markers of Left ventricular Hypertrophy - A Study in Patients with Aortic Valve Stenosis and in the General Population”. Medicinsk Afd. M, Glostrup Hospital. Indregistreret per 1/9 2011.

2011: Hovedvejleder for Henrik Steglich-Arnholm OSVAL II opgave: ”Betydningen af overvægt på den prognostske betydning af N-terminal pro brain nitriuretisk peptid, og andre markører, umiddelbart raske personer”. Medicinsk Afdeling M, Glosrup Hospital. Bestået med 12.

2011: Formand for bedømmelsesudvalg ved ansættelse af adjunkt og udviklingssygeplejerske i kardiologi (delestilling) på OUH

2011: Bedømmer af Skjalg Hassellunds Ph.d.-opgave ved Oslo Universitet: “Effects of Anthocyanin Supplementation on Pathophysiological Markers of Cardiovascular Disease”

2012-: Ph.d.-vejleder for Britta Frederiksen-Møller, ”SYDHOP – SYDdansk Hypertension og Oedem i Præeklampsi studium Sygehus Fyn” Gynækologisk/obstetrisk Afd. D, OUH. Indregistreret 2011.
2012: Hovedvejleder for Thomas Sehested OSVAL II opgave: “Simple cardiovascular risk stratification tools and anthropometric measures
The MORGAM project”. Medicinsk Afdeling M, Glosrup Hospital. Bestået med 12.

2012-13: Vejleder for Kasper Bostlund Assersen, Etårig, prægraduat forsker-uddannelse med projektet: ”Mekanismer bag forhøjet blodtryk: Lokal gennemstrømning i nyrerne ved hypertension” Nuklearmedicinsk Afdeling, OUH. Indregistreret februar 2012.

2012-: Ph.d.-hovedvejleder for Sara Vikström, ”Subklinisk organskade – markører for den enkelte persons følsomhed for den skadelige virkning af risiko faktorer (specielt forhøjet blodtryk og øget alder)” Endokrinologisk Afd. M, OUH. Indregistreret marts 2012.

2012-: Ph.d.-vejleder for Mette Hjortdal Sørensen, ” Biomarkører og koronar kalk. Inflammatoriske- og calcium-fosfatmetaboliske markørers relation til kalk i koronarkarrene” Kardiologisk Afd. B, OUH. Indregistreret maj 2012.

2012-: Ph.d.-vejleder for Jacob Volmer Stidsen, ”Individually tailored treatment in T2D” Endokrinologisk Afd. M, OUH. Indregistreret 2012.

2012-: Ph.d.-hovedvejleder for Marie K. Blicher, ”Kateterbaseret renal denervering hos patienter med behandlingsresistent essentiel hypertension – Effekt på nyre, kar og insulin følsomhed” Endokrinologisk Afd. M, OUH. Indregistreret september 2012.

2012 Bedømmer af Morten Engholm Pedersens Ph.d.-opgave ved Århus Universitet: Vascular Remodelling in Hypertension – Basic and Clinical Aspects” forsvaret 26. oktober 2012.

2012 Bedømmer af Sofia Enhörnings Ph.d.-opgave ved Lunds Universitet: ”The vasopressin system in diabetes, obesity and the metabolic syndrome” forsvaret 14. december 2012.

2013 Formand for bedømmelsesudvalget for Lotte Saabys Ph.d.-opgave ved Syddansk Universitet: “The consequences of the universal 2007 DEFinition of Acute Myocardial Infarction studied prospectively in a Danish consecutive hospital population (DEF-AMI)” forsvaret 3. december 2013.

2014-: Ph.d.-hovedvejleder for Manan Pareek, “Detection of Early Atherosclerosis and Arteriosclerosis using Biomarkers and PET/CT (DETECT) in Healthy Controls and Patients with Hypertension, Type 2 Diabetes, or Carotid Artery Stenosis”.

2014-: Ph.d.-hovedvejleder for Thomas Bastholm Olesen, “HOMA Index based Phenotyping in Type 2 Diabetes – Cardiovascular Characteristics – An ITT Substudy” (HOMAP-CV). Endokrinologisk Afd. M, OUH

2014: Formand for bedømmelsesudvalget for Jane Angel Simonsens Ph.d.-opgave ved Syddansk Universitet: “Prognostisk og prædiktiv værdi af myokardiescintigrafi hos patienter med kronisk iskæmisk hjertesygdom” forsvaret 20. marts 2014.

2014 Hovedvejleder for Søren Diederichsen OSVAL II opgave: “ECG pattern of left ventricular hypertrophy or ST-segment deviation in a healthy population: The impact of fasting glucose and other cardiovascular risk factors”. Endocrinologisk Afdeling M, OUH. Bestået med 12.

2014-: Ph.d.-medvejleder for Monija Mrgan, “Coronary plaque morphology and plaque progression in patients with newly diagnosed type-2 diabetes mellitus”. Kardiologisk Afd., Sydvestjysk Sygehus, Esbjerg

2014-: Post doc vejleder for Trine K. Sønder, Endothelial (dys)function in patients with type 2 diabetes (EDF-T2D). Endokrinologisk Afd. M, OUH

2015-: Ph.d.-hovedvejleder for Mette Lundgren Nielsen, “HOMA Index – As Prognostic Marker in a General Population and as Marker of Metabolic Phenotype in Type 2 Diabetes - An ITT Substudy (HOMAP-Metabolic). Endokrinologisk Afd. M, OUH


Editor
2008: Guest editor in Archives of Medical Science: Special issue on hypertension
2009-12 Member of the Editorial Board of Journal of Hypertension

Reviewer American Heart Journal
American Journal of Hypertension
Atherosclerosis, Blood Pressure
Circulation
Clinical Journal of the American Society of Nephrology
Clinical Physiology and Functional Imaging
Diabetic Medicine
Diabetologia
European Heart Journal
European Journal of Cardiovascular Prevention and Rehabilitation
Heart and Vessel
Hypertension
International Journal of Medical Sciences
Journal of Central Europe Medicine
Journal of Clinical Endocrinology and Metabolism
Journal of Hypertension
Journal of Human Hypertension
Lancet
Vascular Health and Risk Management
Scandinavian Journal of Primary Health Care

Erfaring som koordinator (side 19-21) (administrator og samarbejder)
2000-02: Vagtskema-planlægger for reservelæger.
2001: Ordstyrer, Session om aortaklapsklerose og kardiovaskulær risiko, American College of Cardiology
2005: Ordstyrer, Session om hypertension, American College of Cardiology
2006: Ordstyrer, Session om hypertension og risikostratificering, American College of Cardiology
2006-12: Bestyrelsesmedlem i Dansk Hypertensions Selskab
2007-: Council member of European Society of Hypertension (4-8 år)
2008-11: Synliggørelse og udvidelse af Den Kardiovaskulære Forskningsenhed under Medicinsk afdeling M, Glostrup Hospital
2009-: Medlem af Dansk Cardiologisk Selskabs arbejdsgruppe vedr. Præventiv Kardiologi og Rehabilitering
2006-09: Arrangør af mere end 10 møder (se Kurser og uddannelsesorienterede møder)
2009: Scientific Committee Member European Society of Hypertension Congress in Milan
2010-: Opbygning, koordinering og ledelse af European Society of Hypertensions (ESH) E-learning program til opdatering og reakkreditering af ESH hypertensionsspecialister
2010: Scientific Committee Member og medarrangør European Society of Hypertensions kongres i Oslo
2010: Arrangør og kursusleder af European Society of Hypertensions Master´s Course on Hypertension for læger i Indien.
2010-: Opbygning, koordinering og ledelse af European Society of Hypertensions (ESH) Registry mhp. monitorering af antihypertensiv behandling i Europa samt hjælp til transeuropæisk hypertensionsforskning
2011: Scientific Committee Members International Society of Resistance Arteries congress i Århus
2011: Scientific Committee Member European Society of Hypertension Congress in Milan
2012: Scientific Committee Member European Society of Hypertension Congress in London
2012-: Formand for Forskeruddannelsesprogrammet (FUP) for Hjerte, Nyre og Kredsløb ved Syddansk Universitet


Internationale samarbejdspartnere (samarbejder)

Professor Sverre E. Kjeldsen, Kardiologisk Afdeling, Ullevaal Universitets Hospital, Oslo:
1) Som medvejleder for en af Sverre Kjeldsens Ph.d. studerende Camilla Lund Søraas
2) Som medforfatter på adskillige af mine publikationer på LIFE studiet
3) Som hyppig gæste-foredragsholder ved Dansk Hypertensionsselskabs møder

Professor Lars H. Lindholm, Epidemiology and Public Health Sciences, Public Health and Clinical Medicine, Umeå Universitet, Umeå, Sverige:
1) Som medforfatter på adskillige af mine publikationer på LIFE studiet
2) Som hyppig gæste-foredragsholder ved Dansk Hypertensionsselskabs møder

Professor Richard B. Devereux, Cardiology section, Department of Internal Medicine, Weill Cornell Medical College, New York City, NY, USA:
1) Som medforfatter på adskillige af mine publikationer på LIFE studiet
2) Som fast social/faglig kontakt, når jeg deltager i de amerikanske kongresser

Professor Anna Dominiczak, leder af BHF Glasgow Cardiovascular Research Centre, University of Glasgow, UK:
1) Som tæt samarbejdspartner i the Council of European Society of Hypertension med fokus på et igangværende samarbejde omkring måling af RNA og miRNA i blodprøver fra 2000 konsekutive KAG patienter på Gentofte Hospital som del af Thomas Sehestedts Ph.d

Professor Stephane Laurent, Department of Pharmacology, Hospital Europeen Georges Pompidou, Paris, France:
1) Som tæt samarbejdspartner i the Council of European Society of Hypertension med fokus på et igangværende samarbejde omkring sammenligning af den prognostiske betydning af forskellige mål for subklinisk kardiovaskulær skade udsprunget af Thomas Sehestedts Ph.d

Professor Peter M. Nilsson, Department of Clinical Sciences Medicine, Lund Universitet, Malmø Universitets Hospital, Sverige:
1) Som tæt samarbejdspartner i the Council of European Society of Hypertension med fokus på selskabets hjemmeside

Professor Josep Redon, Hypertension Clinic, Dept. of Internal Medicine,Hospital Clinico, University of Valencia, Spain:
1) Som tæt samarbejdspartner i the Council of European Society of Hypertension med fokus på et igangværende samarbejde med WHOs hovedkontor for ikke infektiøse sygdomme lokaliseret i Hellerup

Professor Kari Kuulasmaa, Department of Health Promotion and Chronic Disease Prevention, National Public Health Institute (KTL), Helsinki, Finland:
1) Som samarbejdspartner på fremtidigt ph.d. projekt omhandlende den store europæiske MORGAN database, som han leder.

Professor Thomas Kahan, Department of Internal Medicine, Karolinska Institute, Stockholm, President of the Swedish Society of Hypertension, Sverige:
1) Som samarbejdspartner ved planlægning af nordiske kurser og møder indenfor hypertension og præventiv kardiologi

Associeret professor Alta E. Schutte, Hypertension in Africa Research Team (HART), North-West University, South Africa:
1) Som samarbejdspartner ved undersøgelse af nye kardiovaskulære risikomarkører blandt hvide og sorte indbyggere i Sydafrika samt hos HIV inficerede:
Fourie CMT, Van Rooyen JM, Kruger A, Olsen MH, Eugen-Olsen J, Schutte AE. SuPAR is associated with metabolic changes in HIV-1 infected Africans three years after enrolling for treatment

Æresbevisninger, legater og anden økonomisk støtte (side 21-23)
1995 Støtte til indkøb af udstyr fra Becket-Fonden og Direktør Jacob Madsens og Olga Madsens Fond (<50.000 kr.fra hver enkelt)
1997 Støtte til analyse af kollagen-markører fra Hjerteforeningen (350.000 kr.)
2002 Kaj og Allis Bunch-Jensens æreslegat for bidrag til kardiovaskulær forskning i Danmark (25.000 kr.)
2005 AstraZeneca Prisen fra Dansk Hypertensionsselskab (25.000 kr.)
2005 Hans Ibsens Fond til Hypertensionsforskningens Fremme (25.000 kr.)
2008 5-årigt klinisk forskningsstipendium fra NOVO Nordisk Fonden (2.500.000 kr.)
2008 European Society of Hypertensions 2-årige Fellowship - Research Grant til Thomas Sehestedt mhp. gennemførsel af hans ph.d. (100.000 Euro)
2008 Støtte til Nordisk ph.d. internatkursus fra The joint Committee of the Nordic Medical Research Councils (NOS-M) (ca. 240.000 kr.)
2008 3-årigt klinisk forskningsstipendium fra FSS (afstået fra modtagelse pga. forskningsstipendium fra NOVO Nordisk Fonden) (1.200.000 kr.)
2010 Et-årigt scholarstipendium fra Lundbeck Fonden til Thomas Sehested (medicinstuderende) (120.000 kr.)
2010 EU støtte gennem Interreg til et forskningssamarbejde i region Øresund mellem Rigshospitalet, Glostrup og Bispebjerg Hospital, Malmø Hospital og Lunds Universitet (1.900.000 Euro)
2011 To etårige Ph.d. stipendium (1.050.000 kr.) fra Novo Nordisk Fonden og OUH til Marie K. Blicher og hendes Ph.d. projekt: Catheter based Renal denervation in patients with Resistant hypertension – Effects on kidney, Vasculature and Insulin SEnsitivity (REVISE)
2012 Et etårigt Ph.d. stipendium (500.000 kr.) og financiel støtte (935.633 kr.) fra Region Syddanmark til Sara Vikström og hendes Ph.d. projekt: SubclinicAl Target Organ damage – a Marker of Individual Cardiovascular Susceptibility (ATOMICS)
2012 Financiel støtte fra Odense Universitetshospital (453.500 + 500.000 kr.) til Ph.d. projekterne ATOMICS og REVISE
2012 European Society of Hypertensions toårige Fellowship - Research Grant til Sara Vikström mhp. gennemførsel af hendes Ph.d. projekt og starte GIRO-TOPIC (100,000 Euro).
2013 5-årigt klinisk forskningsstipendium fra NOVO Nordisk Fonden (2.500.000 kr.)
2013 Financiel støtte fra Hjerteforeningen (425.000 kr.) til Ph.d. projektet REVISE
2013 Financiel støtte fra Odense Universitetshospital (665.000 kr.) til Manan Pareeks Ph.d. projekt: Detection of Early Atherosclerosis and Arteriosclerosis using Biomarkers and PET/CT (DETECT) in Healthy Controls and Patients with Hypertension, Type 2 Diabetes, or Carotid Artery Stenosis.
2013 Et toårigt Ph.d. stipendium (1.050.000 kr.) fra Danish Diabetes Academy til Manan Pareek og DETECT
2013 Et etårigt Ph.d. stipendium (500,000 DKkr.) fra OUH til Manan Pareek og DETECT
2013 Støtte til workshop i arteriesygdom 26 november 2013 (38.000 kr.) fra Danish Diabetes Academy
2013 Støtte til Ph.d. internatkursus i arteriesygdom 7-10 april 2014 (120.000 kr.) fra Danish Diabetes Academy
2014 Et treårigt Post doc stipendium (1,800,000 DKKr.) til Trine K. Sønder fra Danish Diabetes Academy
2014 Et toårigt Ph.d. stipendium (1.050.000 kr.) fra DDA til Thomas Bastholm Olesen og hans Ph.d. projekt: HOMA2 indexed based Phenotyping in Type 2 Diabetes – Cardiovascular Characteristics – An ITT Substudy (HOMAP-CV)
2014: Formand for bedømmelsesudvalget til det kliniske professorat i Interventionel kardiologi ved Det Kliniske Institut under Det Sundhedsvidenskapelige Fakultet, SDU.
2014 Et etårigt Ph.d. stipendium (500.000 kr.) fra Region Syddanmark til Thomas Bastholm Olesen og hans Ph.d. projekt: HOMA2 indexed based Phenotyping in Type 2 Diabetes – Cardiovascular Characteristics – An ITT Substudy (HOMAP-CV)
2014 Et toårigt Ph.d. stipendium (1,050,000 DKkr.) fra DDA til Mette Nielsen og hendes Ph.d. projekt: HOMA index – As a Prognostic Marker in the General Population and as a Marker of Metabolic Phenotype in Type 2 Diabetes Mellitus (HOMAP-Metabolic)
2014 Finansiel støtte fra OUH (288.000 kr.) til Mette Nielsens Ph.d. projekt: HOMAP-Metabolic
2014 Et etårigt Ph.d. stipendium (500.000 kr.) fra Region Syddanmark til Mette Nielsens Ph.d. projekt: HOMAP-Metabolic
2014 Finansiel støtte (200,000 DKkr.) til Manan Pareeks projekt: Sodium Fluoride and Fluorodeoxyglucose Avidity in Carotid Atheroma: Histopathological Correlates (SOFIA) fra Aase og Ejnar Danielsen's Foundation.

Publikationer (Side 23-50) (akademiker)

Kapitler i bøger
1. Can Microalbuminuria be Considered as an Intermediate End-point? Wachtell K and Olsen MH. 2006.
2. Medicinsk behandling af hypertension. Bang LE, Christensen KL, Olsen MH. Medicinhåndbogen 2010 udgivet af Dansk Lægemiddel Information A/S.
3. Midler med virkning på renin-angio¬tensinsystemet. Christensen KL, Olsen MH, Bang LE. Medicinhåndbogen 2010 udgivet af Dansk Lægemiddel Information A/S.
4. Diuretika. Olsen MH, Bang LE, Christensen KL. Medicinhåndbogen 2010 udgivet af Dansk Lægemiddel Information A/S.

Andre Publikationer (letters, editorials or reviews):
1. Wachtell K, Olsen MH, Ibsen H. Response to letter. Ann Intern Medicine 2004;141:245.
2. Ibsen H, Wachtell K, Olsen MH, Borch-Johnsen K, Lindholm LH; Mogensen CE, Dahlöf B. Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: The LIFE Study. Kidney Int 2004;66:S56-8.
3. Höieggen A, Fossum E, Wachtell K, Olsen MH, Reims H, Panish J, Gleim G, Kjeldsen SE, Ibsen H. Hypertension 2002: Year of the LIFE Study. Compendium Series: Cardiovascular 2004;1:4-9.
4. Wachtell K, Lehto M, Gerdts E, Olsen MH, Hornestam B, Dahlöf B, Ibsen H, Julius S, Kjeldsen SE, Lindholm LH, Nieminen MS, Devereux RB. Response to letter. J Am Coll Card 2005;46:1585-1586
5. Wachtell K, Olsen MH, Dahlöf B, Devereux RB. Primary Prevention of Atrial Fibrillation in Hypertensive Patients: What Is New from the LIFE Trial? In Raviele A ed. Cardiac Arrhythmias 2005. Proceedings of 9th International Workshop on Cardiac Arrhythmias. Springer 2005.
6. Wachtell K and Olsen MH. Is it Time to Change the Definition of Normal Urinary Albumin Excretion? Nat Clin Pract Nephrol. 2008 Dec;4(12):650-1. Practice Point commentary on: Forman JP et al J Am Soc Nephrol 2008.
7. Redon J, Cifkova R, Laurent S, Nilsson P, Narkiewicz K, Erdine S, Mancia G; Scientific Council of the European Society of Hypertension. The metabolic syndrome in hypertension: European society of hypertension position statement. J Hypertens. 2008 Oct;26(10):1891-900.
8. Olsen MH, Sehestedt T, Lyngbæk S, Hansen TV, Rasmussen S, Wachtell K, Torp-Pedersen C, Hildebrandt PR, Ibsen H. Urine Albumin/Creatinine Ratio, High Sensitivity C-Reactive Protein and N-Terminal Pro Brain Natriuretic Peptide - Three new Cardiovascular Risk Markers - Do They Improve Risk Prediction and Influence Treatment? Curr Vasc Pharmacol. 2010 Jan;8(1):134-9.
9. Olsen MH, Sehestedt T, Hansen TW, Christensen MK, Gustafsson F, Rasmussen S, Wachtell K, Ibsen H, Torp-Pedersen C, Hildebrandt PR. New cardiovascular risk markers in the general population and in hypertension. Do they improve risk prediction and influence treatment? Arch Med Sci 2009
10. Mancia G, Laurent S, Agabiti-Rosei E, Ambrosioni E, Burnier M, Caulfield MJ, Cifkova R, Clément D, Coca A, Dominiczak A, Erdine S, Fagard R, Farsang C, Grassi G, Haller H, Heagerty A, Kjeldsen SE, Kiowski W, Mallion JM, Manolis A, Narkiewicz K, Nilsson P, Olsen MH, Rahn KH, Redon J, Rodicio J, Ruilope L, Schmieder RE, Struijker-Boudier HA, van Zwieten PA, Viigimaa M, Zanchetti A. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens. 2009; 27(11):2221-58.
11. Mancia G, Laurent S, Agabiti-Rosei E, Ambrosioni E, Burnier M, Caulfield MJ, Cifkova R, Clément D, Coca A, Dominiczak A, Erdine S, Fagard R, Farsang C, Grassi G, Haller H, Heagerty A, Kjeldsen SE, Kiowski W, Mallion JM, Manolis A, Narkiewicz K, Nilsson P, Olsen MH, Rahn KH, Redon J, Rodicio J, Ruilope L, Schmieder RE, Struijker-Boudier HA, van Zwieten PA, Viigimaa M, Zanchetti A. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. Blood Press. 2009;18(6):308-47.
12. Olsen MH. Assessment of Cardiovascular Risk – The Impact and Future of Non-traditional Cardiovascular Risk Markers. European Cardiology 2010;6(2):10–3
13. Sehestedt T, Olsen MH, Subclinical Organ Damage and Cardiovascular Risk Prediction. Blood Press. 2010;19(3):132-9
14. Olsen MH, Mallion JM, Rahn KH, Erdine S, Viigimaa M, Laurent S, Agabiti-Rosei E, Mancia G, Schmieder RE, Cifkova R, Dominiczak A, Kjeldsen SE, Redon J, Zanchetti A, Nilsson P, Narkiewicz K; ESH Council. Agreement within Europe about antihypertensive treatment and education - results from the European Society of Hypertension questionnaire. J Hypertension 2010;28(7):1593-4.
15. Wachtell K, Olsen MH. Impaired left ventricular systolic function in patients with left ventricular hypertrophy. J Hypertens. 2011;29(11):2068-9.
16. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Böhm M, Christiaens T, Cifkova R, De Backer G, Dominiczak A, Galderisi M, Grobbee DE, Jaarsma T, Kirchhof P, Kjeldsen SE, Laurent S, Manolis AJ, Nilsson PM, Ruilope LM, Schmieder RE, Sirnes PA, Sleight P, Viigimaa M, Waeber B, Zannad F; ESH Scientific Council, Redon J, Dominiczak A, Narkiewicz K, Nilsson PM, Burnier M, Viigimaa M, Ambrosioni E, Caufield M, Coca A, Olsen MH, Schmieder RE, Tsioufis C, van de Borne P. 2013 ESH/ESC Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013;34(28):2159-219.
17. Mancia G, Fagard R, Narkiewicz K, Redón J, Zanchetti A, Böhm M, Christiaens T, Cifkova R, De Backer G, Dominiczak A, Galderisi M, Grobbee DE, Jaarsma T, Kirchhof P, Kjeldsen SE, Laurent S, Manolis AJ, Nilsson PM, Ruilope LM, Schmieder RE, Sirnes PA, Sleight P, Viigimaa M, Waeber B, Zannad F; Task Force Members. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013;31(7):1281-357.

Artikler nationalt
18. Wachtell K, Ibsen H, Olsen MH, Layborn C, Christoffersen JK, Nørgaard H, Mantoni M, Lund JO. Prevalence of renal artery stenosis in patients with peripheral vascular di¬sease and hypertension. ¬Ugeskrift for Læger 1997;46:6822-24.
19. Olsen MH. Det kardiovaskulære Metaboliske Syndrom. Lægemagasinet 1998;6:12-14.
20. Olsen MH, Ibsen H, Mogensen CE. Mikroalbuminuri. Ugeskrift for Læger 2009;25:2097-2100
21. Olsen MH, Sehestedt T, Prescott E. Den kardiovaskulære risikoprofil og antihypertensiv behandling. Ugeskrift for Læger 2009;24:2008-11
22. Olsen MH, Jeppesen J, Larsen ML. Hypertension og det metaboliske syndrom. Ugeskrift for Læger 2009;25:2107-09
23. Olsen MH. Nye kardiovaskulære risikofaktorer. BestPractice 2010;1:28.
24. Buus NH, Mathiassen ON, Andersen UB, Olsen MH. Kateter-baseret renal denervering. Ugeskr Laeger. 2012 Mar 19;174(12):789.
Artikler internationalt (108, hvoraf 33 som 1. forfatter og 13 som sidste forfatter, 45 i løbet af de sidste 5 år, de 24 vigtigste er markeret med fed)
H-index: 32. Number of citations: 3680 (without selfcitation 3599). Citations / paper: 20
25. Olsen NV, Olsen MH, Fogh-Andersen N, Feldt-Rasmussen B, Kamper A, Plum I, Strandgaard S, Leyssac PP. Lithium clearance method and the renal response to low-dose dopamine in man: a randomized, controlled study. Clinical Science 1993; 84:237-42.
26. Wachtell K, Ibsen H, Olsen MH, Layborn C, Christoffersen JK, Nørgaard H, Mantoni M, Lund JO. Prevalence of renal artery stenosis in patients with peripheral vascular di¬sease and hypertension. J Hum Hypertens 1996;10:83-85.
27. Olsen NV, Olsen MH, Bonde J, Kanstrup IL, Plum I, Strand¬gaard S, Leyssac PP. Dopamine natriure¬sis in salt-repleted, water-loaded humans: a dose-response study. British Journal of Clinical Pharmacology 1997;43:509-520.
28. Olsen MH, Andersen UB, Wachtell K, Ibsen H, Dige-Petersen H. Influence of non-steady state during isoglycemic hyperinsulinemic clamp in hypertension. A LIFE substudy. Blood Pressure 1999;8:207-213.
29. Olsen MH, Fossum E, Hjerkinn E, Wachtell K, Høieggen A, Nesbitt SD, Andersen UB, Phillips RA, Gaboury CL, Ibsen H, Kjeldsen SE, Julius S. Relative Influence of insulin resistance versus blood pressure on vascular changes in longstanding hypertension. ICARUS, a LIFE substudy. J Hypertens 2000;18:75-81.
30. Olsen MH, Andersen UB, Wachtell K, Ibsen H, Dige-Petersen H. A possible link between endothelial dysfunction and insulin resistance in hypertension. A LIFE substudy. Blood Pressure 2000;9:132-139.
31. Olsen MH, Wachtell K, Hermann KL, Bella JN, Andersen UB, Dige-Petersen H, Rokkedal J, Ibsen H. Maximal exercise capacity is closely related to cardiovascular structure in patients with longstanding hypertension. A LIFE substudy. Am J Hypertens 2001;14:1205-1210
32. Olsen MH, Wachtell K, Aalkjaer C, Devereux RB, Dige-Petersen H, Ibsen H. Endothelial Dysfunction in Resistance Arteries is Related to High Blood Pressure and Circulating Low Density Lipoproteins in Previously Treated Hypertension. Am J Hypertens 2001;14:861-867.
33. Olsen MH, Wachtell K, Aalkjaer C, Dige-Petersen H, Rokkedal J, Ibsen H. Vasodilatory capacity and vascular structure in patients with longstanding hypertension. A LIFE substudy. Am J Hypertens 2002;15(5):398-404.
34. Olsen MH, Wachtell K, Hermann KL, Frandsen E, Dige-Petersen H, Rokkedal J, Devereux RB, Ibsen H. Is cardiovascular remodeling in patients with essential hypertension related to more than high blood pressure? A LIFE substudy. Am Heart J 2002;144(3):530-7.
35. Olsen MH, Wachtell K, Okin PM, Kjeldsen SE, Dahlöf B, Devereux RB, Borch-Johnsen K, Ibsen H. A Blood Pressure Independent Association between Glomerular Albumin Leakage and Electrocardiographic Left Ventricular Hypertrophy. The LIFE Study. J Hum Hypertens 2002;16:591-5
36. Olsen MH, Wachtell K, Hermann KL, Bella JN, Dige-Petersen H, Rokkedal J, Ibsen H. Left ventricular hypertrophy is associated with reduced vasodilatory capacity in the brachial artery in patients with longstanding hypertension. A LIFE substudy. Blood Pressure 2002;11:1-8
37. Olsen MH, Hjerkinn E, Wachtell K, Høieggen A, Bella JN, Nesbitt SD, Fossum E, Kjeldsen SE, Julius S, Ibsen H. Are Left Ventricular Mass, Geometry and Function Related to Vascular Changes and/or Insulin Resistance in Longstanding Hypertension. A LIFE Substudy. J Hum Hypertens 2003;17:305-11
38. Olsen MH, Wachtell K, Meyer C, Hove JD, Palmieri V, Dige-Petersen H, Rokkedal J, Hesse B, Ibsen H. Association between vascular dysfunction and reduced myocardial flow reserve in patients with hypertension and left ventricular hypertrophy. A LIFE substudy. J Hum Hypertens 2004;18:445-452
39. Olsen MH, Wachtell K, Palmieri V, de Simone G, Dige-Petersen H, Ibsen H, Devereux RB, Rokkedal J. Is Inappropriate Left Ventricular Mass Related to Neuro-hormonal Factors and/or Vascular Changes in Hypertension. A LIFE Substudy. J Hum Hypertens 2004;18:437-443
40. Olsen MH, Wachtell K, Bella JN, Palmieri V, Gerdts E, Nieminen MS, Smith G, Dahlöf B, Ibsen H, Devereux RB. Albuminuria Predicts Cardiovascular Events Independently of Left Ventricular Mass in Hypertension. A LIFE Substudy. J Hum Hypertens 2004;18:453-459
41. Olsen MH, Wachtell K, Tuxen C, Fossum E, Bang L, Hall C, Ibsen H, Rokkedal J, Devereux RB, Hildebrandt P. N-terminal proBrain Natriuretic Peptide Predict Cardiovascular Events in Patients with Hypertension and Left Ventricular Hypertrophy. A LIFE Substudy. J Hypertens 2004; 22(8):1597-1604.
42. Olsen MH, Wachtell K, Bella JN, Liu JE, Boman K, Gerdts E, Papademetriou V, Nieminen MS, Rokkedal J, Dahlöf B, Devereux RB. Effect of losartan versus atenolol on aortic valve sclerosis (a LIFE substudy). Am J Cardiol 2004; 94(8):1076-1080.
43. Olsen MH, Wachtell K, Bella JN, Gerdts E, Palmieri V, Nieminen M, Smith G, Kjeldsen SE, Dahlöf B, Ibsen H, Devereux RB. Aortic valve sclerosis relates to cardiovascular events in patients with hypertension (a LIFE substudy). Am J Cardiol 2005; 95(1):132-136.
44. Olsen MH, Christensen MK, Wachtell K, Tuxen C, Hjerkinn E, Bang LE, Wiinberg N, Christensen MK, Rokkedal J, Hildebrandt P, Palmieri V, Frandsen E, Kjeldsen SE, Dige-Petersen H, Ibsen H, Jensen LT. Markers of collagen synthesis is related to blood pressure and vascular hypertrophy: a LIFE substudy. J Hum Hypertens 2005; 19(4):301-7.
45. Olsen MH, Wachtell K, Tuxen C, Fossum E, Bang L, Hall C, Ibsen H, Rokkedal J, Devereux RB, Hildebrandt P. Opposite Effects of Losartan and Atenolol on Natriuretic Peptides in Patients with Hypertension and Left Ventricular Hypertrophy. A LIFE Study. J Hypertension 2005; 23(5):1083-90.
46. Olsen MH, Fossum E, Wachtell K, Høieggen A, Hjerkinn E, Kjeldsen SE, Dige-Petersen H, Julius S, Ibsen H. Long-term treatment with losartan versus atenolol improves insulin sensitivity in hypertension: ICARUS, a LIFE substudy. J Hypertens 2005; 23(4):891-8.
47. Olsen MH, Wachtell K, Neland K, Rokkedal J, Ibsen H, Dige-Petersen H. Losartan and not Atenolol Reduce Carotid Artery Hypertrophy in Essential Hypertension. A LIFE Substudy. Blood Pressure 2005;14(3):177-83.
48. Olsen MH, Wachtell K, Bella JN, Palmieri V, Gerdts E, Nieminen MS, Smith G, Dahlöf B, Ibsen H, Devereux RB. Aortic Valve Sclerosis and Albuminuria Independently Predict Cardiovascular Events in Hypertension. A LIFE Substudy. Am J Hypertension 2005;18:1430-36.
49. Olsen MH, Hansen TW, Christensen MK, Gustafsson F, Rasmussen S, Wachtell K, Borch-Johnsen K, Ibsen H, Jørgensen T, Hildebrandt P. Nt-pro brain natriuretic peptide is inversely related to metabolic cardiovascular risk factors and the metabolic syndrome. Hypertension 2005;46:1-7
50. Olsen MH, Christensen MK, Hansen TW, Gustafsson F, Rasmussen S, Wachtell K, Borch-Johnsen K, Ibsen H, Jørgensen T, Hildebrandt P. High sensitivity C-reactive protein is related to cardiovascular damage, but not independently of cardiovascular risk factors. J Hypertens 2006;24(4):655-61
51. Olsen MH, Wachtell K, Dahlof B, Devereux RB, Ibsen H, Kjeldsen SE, Lindholm LH, Lyle PA, Nieminen MS. The effect of losartan compared with atenolol on the incidence of revascularization in patients with hypertension and electrocardiographic left ventricular hypertrophy. The LIFE study. J Hum Hypertens 2006;20(6):460-4
52. Olsen MH, Wachtell K, Ibsen H, Lindholm LH, Dahlof B, Devereux RB, Kjeldsen SE, Oikarinen L, Okin PM. Reductions in albuminuria and in electrocardiographic left ventricular hypertrophy independently improve prognosis in hypertension: the LIFE study. J Hypertens 2006;24(4):775-81
53. Olsen MH, Wachtell K, Nielsen OW, Hall C, Wergeland R, Ibsen H, Kjeldsen SE, Devereux RB, Dahlof B, Hildebrandt PR. N-terminal brain natriuretic peptide predicted cardiovascular events stronger than high-sensitivity C-reactive protein in hypertension: a LIFE substudy. J Hypertens 2006;24(8):1531-9
54. Olsen MH, Hansen TW, Christensen MK, Rasmussen S, Wachtell K, Borch-Johnsen K, Ibsen H, Jørgensen T, Hildebrandt P. N-terminal pro brain natriuretic peptide, but not high sensitivity C-reactive protein improves cardiovascular risk prediction in the general population. European Heart Journal 2007;28:1374-81
55. Olsen MH, Hansen TW, Christensen MK, Gustafsson F, Rasmussen S, Wachtell K, Ibsen H, Christian Torp-Pedersen, Hildebrandt P. Cardiovascular risk prediction by N-terminal pro brain natriuretic peptide and high sensitivity C-reactive protein is affected by age and gender. J Hypertension 2008;26(1):26-34
56. Olsen MH, Hansen TW, Christensen MK, Gustafsson F, Rasmussen S, Wachtell K, Ibsen H, Christian Torp-Pedersen, Hildebrandt P. Impact of the metabolic syndrome on the predictive values of new risk markers in the general population. J Hum Hypertens 2008;22:634-40.
57. Olsen MH, Hansen TW, Christensen MK, Gustafsson F, Rasmussen S, Wachtell K, Ibsen H, Christian Torp-Pedersen, Hildebrandt P. New risk markers may change the HeartScore risk-classification significantly in one fifth of the population. J Hum Hypertens 2008;23(2):105-112.
58. Olsen MH, Wachtell K, Beevers G, Dahlöf B, Devereux RB, de Faire U, Fyhrquist F, Ibsen H, Kjeldsen SE, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H. The prognostic importance of hemoglobin in patients with hypertension and electrocardiographic left ventricular hypertrophy. The LIFE Study. Am Heart J. 2009;157(1):177-84
59. Olsen MH, Wachtell K, Beevers G, Dahlöf B, Devereux RB, de Faire U, Fyhrquist F, Ibsen H, Julius S, Kjeldsen SE, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H. Losartan has Positive Effects on Lipid Metabolism Compared to Atenolol in Patients with Hypertension and Electrocardiographic Left Ventricular Hypertrophy. The LIFE Study. J Hypertens 2009;27(3):567-74
60. Olsen MH, Wachtell K, Ibsen H, Lindholm LH, Kjeldsen SE, Omvik P, Nieminen MS, Dahlöf B, Okin PM, Devereux RB. Changes in subclinical organ damage versus Framingham risk score for assessing cardiovascular risk reduction during continued antihypertensive treatment. A LIFE Sustudy. J Hypertens 2011;29(5):997-1004.
61. Wachtell K, Palmieri V, Olsen MH, Bella JN, Aalto T, Dahlöf B, Gerdts E, Borch-Johnsen K, Rokkedal J, Ibsen H, Devereux RB. Urine Albunin/Creatinine Ratio and Echocardiographic Left Ventricular Structure and Function in Hypertensive Patients with Electrocardiographic Left Ventricular Hypertrophy. Am Heart J 2002;143(2):319-26.
62. Bella JN, Wachtell K, Boman K, Palmieri V, Papademetriou V, Gerdts E, Aalto T, Olsen MH, Olofsson M, Dahlöf B, Roman MJ, Devereux RB. Relation of Left Ventricular Geometry and Function to Aortic Root Dilatation in Patients with systemic Hypertension and Left Ventricular Hypertrophy: The LIFE Study. Am J Cardiol 2002;89:337-341.
63. Wachtell K, Olsen MH, Dahlöf B, Devereux RB, Jern S, Julius S, Kjeldsen SE, Nieminen MS, Omvik P, Okin PM, Mogensen CE, Borch-Johnsen K, Ibsen H. Microalbuminuria in Hypertensive Patients Electrocardiographic Left Ventricular Hypertrophy. The LIFE Study. J Hypertens 2002;20(3):405-12.
64. Wachtell K, Palmieri V, Olsen MH, Gerdts E, Papademetriou V, Nieminen MS, Smith G, Dahlöf B, Aurigemma GP, Devereux RB. Change in Systolic Left Ventricular Performance After Three Years of Antihypertensive Treatment: The LIFE Study. Circulation 2002;106(2);227-32.
65. Lindholm LH, Ibsen H, Borch-Johnsen K, Olsen MH, Wachtell K, Dahlöf B, Devereux RB, Beevers G, de Faire U, Fyhrquist F, Julius S, Kjeldsen SE, Kristianson K, Lederballe-Pedersen O, Nieminen MS, Omvik P, Oparil S, Wedel H, Aurup P, Edelman J, Snapinn S. Risk of new-onset diabetes in the losartan intervention for endpoint reduction in hypertension study. J Hypertens 2002;20:1879-86.
66. Lindholm LH, Dahlöf B, Edelman JM, Ibsen H, Borch-Johnsen K, Olsen MH, Snapinn S, Wachtell K, for the LIFE study group. Less Sudden Cardiac Death in Diabetics Treated with Losartan – Data From the LIFE Trial. Lancet 2003;362:619-20.
67. Wachtell K, Ibsen H, Olsen MH, Borch-Johnsen K, Lindholm LH, Mogensen CE, Dahlöf B, Devereux RB, Beevers G, de Faire U, Fyhrquist F, Julius S, Kjeldsen SE, Kristianson K, Lederballe-Pedersen O, Nieminen MS, Okin PM, Omvik P, Oparil S, Wedel H, Snapinn SM, Aurup P. Albuminuria and Cardiovascular Risk in Hypertensive Patients with Left Ventricular Hypertrophy: The LIFE Study. Ann Internal Med 2003;139:601-9
68. Hildebrandt P, Boesen M, Olsen MH, Wachtell K, Groenning B. N-terminal Pro Brain Natriuretic Peptide in Arterial Hypertension - a Marker for Left Ventricular Dimensions and Prognosis. Eur J Heart Fail. 2004;6:313-7
69. Fossum E, Olsen MH, Høieggen A, Wachtell K, Reims H, Ibsen H, Julius S, Kjeldsen SE. Long-Term Plasma Catecholamine Levels in Patients with Hypertension and Left Ventricular Hypertrophy Treated with Losartan or Atenolol. ICARUS, a LIFE Substudy. J Hum Hypertens 2004;18:375-380
70. Wiinberg N, Bang LE, Wachtell K, Larsen J, Olsen MH, Tuxen C, Hildebrandt PR, Rokkedal J, Ibsen H, Devereux RB. 24-hour Ambulatory Blood Pressure and Urinary Albumin Excretion in Patients with ECG Determined Left Ventricular Hypertrophy: The LIFE Study. J Hum Hypertens 2004;18:391-396
71. Ibsen H, Wachtell K, Olsen MH, Borch-Johnsen K, Lindholm LH, Mogensen CE, Dahlöf B, Devereux RB, Beevers G, de Faire U, Fyhrquist F, Julius S, Kjeldsen SE, Lederballe Pedersen O, Nieminen MS, Okin PM, Omvik P, Oparil S, Snapinn S, Wedel H. Does Albuminuria Predict Cardiovascular Outcome on Treatment with Losartan Versus Atenolol in Patients with Hypertension and Left Ventricular Hypertrophy? A LIFE substudy. J Hypertens 2004; 22(9):1805-1811.
72. Ibsen H, Wachtell K, Olsen MH, Borch-Johnsen K, Lindholm LH, Mogensen CE, Dahlöf B, Devereux RB, Beevers G, de Faire U, Fyhrquist F, Julius S, Kjeldsen SE, Lederballe Pedersen O, Nieminen MS, Okin PM, Omvik P, Oparil S, Snapinn S, Wedel H. Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE Study. Kidney Int Suppl 2004;(92):S56-S58.
73. Andersen UB, Olsen MH, Dige-Petersen H, Ibsen H. Exercise blood pressure is related to insulin resistance in subjects with two hypertensive parents. Blood Press. 2003;12(5-6):314-8
74. Ibsen H, Olsen MH, Wachtell K, Borch-Johnsen K, Lindholm LH, Mogensen CE, Dahlof B, Devereux RB, de Faire U, Fyhrquist F, Julius S, Kjeldsen SE, Lederballe-Pedersen O, Nieminen MS, Omvik P, Oparil S, Wan Y. Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study. Hypertension. 2005;45(2):198-202.
75. Wachtell K, Hornestam B, Lehto M, Slotwiner DJ, Gerdts E, Olsen MH, Aurup P, Dahlof B, Ibsen H, Julius S, Kjeldsen SE, Lindholm LH, Nieminen MS, Rokkedal J, Devereux RB. Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation: The Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol. 2005;45(5):705-11
76. Wachtell K, Lehto M, Gerdts E, Olsen MH, Hornestam B, Dahlof B, Ibsen H, Julius S, Kjeldsen SE, Lindholm LH, Nieminen MS, Devereux RB. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol. 2005;45(5):712-9
77. Franklin SS, Wachtell K, Papademetriou V, Olsen MH, Devereux RB, Fyhrquist F, Ibsen H, Kjeldsen SE, Dahlof B.Cardiovascular morbidity and mortality in hypertensive patients with lower versus higher risk: a LIFE substudy. Hypertension. 2005;46(3):492-9
78. Kjaer A, Meyer C, Wachtell K, Olsen MH, Ibsen H, Opie L, Holm S, Hesse B. Positron emission tomographic evaluation of regulation of myocardial perfusion in physiological (elite athletes) and pathological (systemic hypertension) left ventricular hypertrophy.Am J Cardiol. 2005;96(12):1692-8
79. Ibsen H, Olsen MH, Wachtell K, Borch-Johnsen K, Lindholm LH, Mogensen CE, Dahlof B, Snapinn SM, Wan Y, Lyle PA. Does albuminuria predict cardiovascular outcomes on treatment with losartan versus atenolol in patients with diabetes, hypertension, and left ventricular hypertrophy? The LIFE study.Diabetes Care. 2006;29(3):595-600
80. Christensen MK, Olsen MH, Wachtell K, Bang LE, Tuxen C, Hjerkinn E, Rokkedal J, Frandsen E, Hildebrandt P, Kjeldsen SE, Ibsen H, Dige-Petersen H. Effect of Losartan versus Atenolol on Circulating Collagen Markers and the Prognostic Value of Changes in these Markers. A LIFE Substudy. Blood Press 2006;15:198-206.
81. Fossum E, Olsen MH, Hoieggen A, Wachtell K, Reims HM, Kjeldsen SE, Ibsen H, Wan Y, Julius S. Long-term effects of a losartan- compared with an atenolol-based treatment regimen on carotid artery plaque development in hypertensive patients with left ventricular hypertrophy: ICARUS, a LIFE substudy. J Clin Hypertens (Greenwich). 2006;8(3):169-73.
82. Eijkelkamp WB, Zhang Z, Brenner BM, Cooper ME, Devereux RB, Dahlof B, Ibsen H, Keane WF, Lindholm LH, Olsen MH, Parving HH, Remuzzi G, Shahinfar S, Snapinn SM, Wachtell K, de ZD. Renal function and risk for cardiovascular events in type 2 diabetic patients with hypertension: the RENAAL and LIFE studies. J Hypertens 2007;25(4):871-6.
83. Bang LE, Wiinberg N, Wachtell K, Larsen J, Olsen MH, Tuxen C, Hildebrandt PR, Ibsen H. Losartan versus atenolol on 24-hour ambulatory blood pressure. A LIFE substudy. Blood Press 2007;16(6):392-7.
84. Wachtell K, Okin PM, Olsen MH, Dahlof B, Devereux RB, Ibsen H, Kjeldsen SE, Lindholm LH, Nieminen MS, Thygesen K. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive therapy and reduction in sudden cardiac death: the LIFE Study. Circulation 2007;116(7):700-5
85. de SG, Olsen MH, Wachtell K, Hille DA, Dahlof B, Ibsen H, Kjeldsen SE, Lyle PA, Devereux RB. Clusters of metabolic risk factors predict cardiovascular events in hypertension with target-organ damage: the LIFE study. J Hum Hypertens 2007;21(8):625-32
86. Smebye ML, Iversen EK, Hoieggen A, Flaa A, Os I, Kjeldsen SE, Olsen MH, Chattopadhyay A, Hille DA, Lyle PA, Devereux RB, Dahlof B. Effect of hemoglobin levels on cardiovascular outcomes in patients with isolated systolic hypertension and left ventricular hypertrophy (from the LIFE study). Am J Cardiol 2007;100(5):855-9
87. Okin PM, Wachtell K, Devereux RB, Nieminen MS, Oikarinen L, Viitasalo M, Toivonen L, Ibsen H, Olsen MH, Borch-Johnsen K, Lindholm LH, Kjeldsen SE, Julius S, Dahlof B. Combination of the Electrocardiographic Strain Pattern and Albuminuria for the Prediction of New-onset Heart Failure in Hypertensive Patients: The LIFE Study. Am J Hypertens 2008;21:273-279
88. Ibsen H, Olsen MH, Wachtell K, Borch-Johnsen K, Lindholm LH, Mogensen CE. Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients with left ventricular hypertrophy and diabetes. J Nephrol. 2008;21(4):566-9.
89. Pedersen SA, Galatius S, Olsen MH, Madsen BK, Madsen JK, Nielsen OW. High prevalence of risk factors in coronary artery disease in EUROPA gives HOPE for ACE inhibitors after PEACE. Cardiology 2008;111(1):63-7.
90. Jeppesen J, Hansen TW, Olsen MH, Rasmussen S, Ibsen H, Torp-Pedersen C, Hildebrandt PR, Madsbad S. C-reactive protein, insulin resistance and risk of cardiovascular disease: a population-based study. Eur J Cardiovasc Prev Rehabil. 2008;15(5):594-8.
91. de Simone G, Okin PM, Gerdts E, Olsen MH, Wachtell K, Hille DA, Dahlöf B, Kjeldsen SE, Devereux RB. Clustered metabolic abnormalities blunt regression of hypertensive left ventricular hypertrophy: the LIFE study. Nutr Metab Cardiovasc Dis. 2009;19(9):634-40.
92. Sehestedt T, Jeppesen J, Hansen TW, Rasmussen S, Wachtell K, Ibsen H, Torp-Petersen C, Olsen MH. Which markers of subclinical organ damage to measure in subjects with high normal blood pressure? J Hypertens 2009;27(6):1165-71.
93. Sehestedt T, Jeppesen J, Hansen TW, Rasmussen S, Wachtell K, Ibsen H, Torp Petersen C, Olsen MH. Risk stratification with the risk chart from the European Society of Hypertension compared with SCORE in the general population. J Hypertens 2009;27(12):2351-7
94. Sehestedt T, Jeppesen J, Hansen TW, Wachtell K, Ibsen H, Torp-Petersen C, Hildebrandt PR, Olsen MH. Risk stratification is improved by adding markers of subclinical organ damage to SCORE. Eur Heart J. 2010;31(7):883-91
95. Wachtell K, Gerdts E, Aurigemma GP, Boman K, Dahlöf B, Nieminen MS, Olsen MH,Okin PM, Palmieri V, Rokkedal JE, Devereux RB.In-treatment reduced left atrial diameter during antihypertensive treatment is associated with reduced new-onset atrial fibrillation in hypertensive patients with left ventricular hypertrophy: The LIFE Study. Blood Press. 2010;19(3):169-75.
96. Wiik BP, Larstorp AC, Høieggen A, Kjeldsen SE, Olsen MH, Ibsen H, Lindholm L, Dahlöf B, Devereux RB, Okin PM, Wachtell K.Serum Uric Acid Is Associated With New-Onset Diabetes in Hypertensive Patients With Left Ventricular Hypertrophy: The LIFE Study. Am J Hypertens. 2010;23(8):845-51
97. Søraas CL, Wachtell K, Okin PM, Dahlöf B, Devereux RB, Tønnessen T, Kjeldsen SE, Olsen MH. Lack of regression of left ventricular hypertrophy is associated with higher incidence of revascularization in hypertension: The LIFE Study. Blood Press. 2010;19(3):145-51.
98. Wachtell K, Gerdts E, Palmieri V, Olsen MH, Nieminen MS, Papademetriou V, Boman K, Dahlöf B, Aurigemma GP, Rokkedal JE, Devereux RB. In-treatment midwall and endocardial fractional shortening predict cardiovascular outcome in hypertensive patients with preserved baseline systolic ventricular function: the Losartan Intervention For Endpoint reduction study. J Hypertens. 2010;28(7):1541-6
99. Sehested TS, Hansen TW, Olsen MH, Abildstrøm SZ, Rasmussen S, Ibsen H,Torp-Pedersen C, Madsbad S, Jeppesen J. Measures of overweight and obesity and risk of cardiovascular disease: a population-based study. Eur J Cardiovasc Prev Rehabil. 2010;17(4):486-90.
100. Eugen-Olsen J, Andersen O, Linneberg A, Ladelund S, Hansen TW, Langkilde A, Petersen J, Pielak T, Møller LN, Jeppesen J, Lyngbæk S, Fenger M, Olsen MH, Hildebrandt PR, Borch-Johnsen K, Jørgensen T, Haugaard SB. Circulating soluble urokinase plasminogen activator receptor predicts cancer, cardiovascular disease, diabetes and mortality in the general population. J Internal Medicine 2010;268(3):296-308.
101. Larstorp ACK, Okin PM, Devereux RB, Olsen MH, Ibsen H, Dahlô B, Kjeldsen SE, Wachtell K. Changes in electrocardiographic left ventricular hypertrophy and risk of major cardiovascular events in isolated systolic hypertension: The LIFE study. J Hum Hypertens 2011;25(3):178-85
102. Sehestedt T, Lyngbæk S, Eugen-Olsen J, Jeppesen J, Andersen O, Hansen TW, Linneberg A, Jørgensen T, Haugaard SB, Olsen MH. Soluble urokinase plasminogen activator receptor is associated with subclinical organ damage and cardiovascular events. Atherosclerosis 2011;216(1):237-43.
103. Schutte AE, Myburgh A, Olsen MH, Eugen-Olsen J, Schutte R. Exploring soluble urokinase plasminogen activator receptor and its relationship with arterial stiffness in a bi-ethnic population: the SAfrEIC-study. Thromb Res Accepted 30 Oct 2011.
104. Kruger R, Schutte R, Huisman HW, Hindersson P, Olsen MH, Schutte AE. N-terminal prohormone B-type natriuretic peptide and cardiovascular function in Africans and Caucasians: the SAfrEIC study. Heart, Lung and Circulation 2012;21(2):88-95
105. Redon J, Olsen MH, Cooper RS, Zurriaga O, Martinez-Beneito MA, Laurent S,Cifkova R, Coca A, Mancia G. Stroke mortality and trends from 1990 to 2006 in 39 countries from Europe and Central Asia: implications for control of high blood pressure. Eur Heart J. 2011;32(11):1424-31.
106. Fourie CM, Van Rooyen JM, Kruger A, Olsen MH, Eugen-Olsen J, Schutte R,Schutte AE. Soluble Urokinase Plasminogen Activator Receptor (suPAR) is Associated with Metabolic Changes in HIV-1-Infected Africans: A Prospective Study. Inflammation 2012; 35(1):221-231.
107. ARB Trialists Collaboration. Effects of telmisartan, irbesartan, valsartan,candesartan, and losartan on cancers in 15 trials enrolling 138,769 individuals. J Hypertens. 2011;29(4):623-35.
108. Sehestedt T, Jeppesen J, Hansen TW, Rasmussen S, Wachtell K, Ibsen H, Torp-Petersen C, Olsen MH. Can ambulatory blood pressure measurements substitute assessment of subclinical cardiovascular damage? J Hypertens 2012;30(3):513-21.
109. Kruger R, Schutte R, Huisman HW, Argraves WS, Rasmussen LM, Olsen MH, Schutte AE. NT-proBNP is associated with fibulin-1 in Africans: the SAfrEIC study. Atherosclerosis 2012;222(1):216-21.
110. Ruwald AH, Westergaard B, Sehestedt T, Kjeldsen SE, Lindholm LH, Wachtell K, Devereux RB, Ibsen H, Nieminen MS, Dahlöf B, Olsen MH. Losartan- versus atenolol-based antihypertensive treatment reduces cardiovascular events especially well in elderly patients: The Losartan Intervention For Endpoint reduction in hypertension (LIFE) Study. J Hypertens 2012;30(6):1252-9.
111. Jeppesen JL, Nielsen SJ, Torp-Pedersen C, Hansen TW, Olsen MH, Berg ND,Linneberg A, Madsbad S, Fenger M. Genetic Variation in the Natriuretic Peptide System, Circulating Natriuretic Peptide Levels, and Blood Pressure: An Ambulatory Blood Pressure Study. Am J Hypertens. 2012;25(10):1095-100
112. Larstorp AC, Ariansen I, Gjesdal K, Olsen MH, Ibsen H, Devereux RB, Okin PM,Dahlöf B, Kjeldsen SE, Wachtell K. Association of Pulse Pressure With New-Onset Atrial Fibrillation in Patients With Hypertension and Left Ventricular Hypertrophy: The Losartan Intervention For Endpoint (LIFE) Reduction in Hypertension Study. Hypertension 2012;60(2)347-53.
113. Larstorp AC, Okin PM, Devereux RB, Olsen MH, Ibsen H, Dahlöf B, Kjeldsen SE, Wachtell K. Regression of ECG-LVH is Associated with Lower Risk of New-Onset Heart Failure and Mortality in Patients with Isolated Systolic Hypertension; The LIFE Study. Am J Hypertens. 2012:25(10):1101-9
114. Greve AM, Olsen MH, Bella JN, Lønnebakken MT, Gerdts E, Okin PM, Palmieri V,Boman K, Nieminen MS, Omvik P, Dahlöf B, Devereux RB, Wachtell K. Contrasting Hemodynamic Mechanisms of Losartan- vs. Atenolol-Based Antihypertensive Treatment: A LIFE Study. Am J Hypertens. 2012;25(9):1017-23.
115. Ariansen I, Reims HM, Gjesdal K, Olsen MH, Ibsen H, Devereux RB, Okin PM,Kjeldsen SE, Dahlöf B, Wachtell K. Impact of alcohol habits and smoking on the risk of new-onset atrial fibrillation in hypertensive patients with ECG left ventricular hypertrophy: the LIFE study. Blood Press. 2012;21(1):6-11
116. Haugaard SB, Andersen O, Hansen TW, Eugen-Olsen J, Linneberg A, Madsbad S, Olsen MH, Jørgensen T, Borch-Johnsen K, Jeppesen J. The immune marker soluble urokinase plasminogen activator receptor is associated with new-onset diabetes in non-smoking women and men. Diabet Med. 2012;29(4):479-87.
117. Sehestedt T, Jeppesen J, Hansen TW, Rasmussen S, Wachtell K, Ibsen H, Torp-Pedersen C, Olsen MH. Thresholds for pulse wave velocity, urine albumin creatinine ratio and left ventricular mass index using SCORE, Framingham and ESH/ESC risk charts. J Hypertens. 2012;30(10):1928-36.
118. Vishram JKK, Borglykke A, Andreasen AH, Jeppesen J, Ibsen H, Jørgensen T, Broda G, Palmieri L, Giampaoli S, Donfrancesco C, Kee F, Mancia G, Cesana G, Kuulasmaa K, Sans S, Olsen MH. The MOnica, Risk, Genetics, Archiving, and Monograph (MORGAM) Project Impact of Age on the Importance of Systolic and Diastolic Blood Pressures for Stroke Risk. Hypertension 2012;60(5):1117-1123.
119. Kruger R, Schutte R, Huisman HW, Olsen MH, Schutte AE. NT-proBNP and potential vascular calcification in Black and Caucasian African men: the SAfrEIC study. Ethn Dis. 2012;22(4):398-403.
120. Lyngbæk S, Marott JL, Sehestedt T, Hansen TW, Olsen MH, Andersen O, Linneberg A, Haugaard SB, Eugen-Olsen J, Hansen PR, Jeppesen J. Cardiovascular risk prediction in the general population with use of suPAR, CRP, and Framingham Risk Score. Int J Cardiol. 2013;167(6):2904-11
121. De Marco M, Gerdts E, Casalnuovo G, Migliore T, Wachtell K, Boman K, Dahlof B, Olsen MH, Kizer JR, Devereux RB, De Simone G, Mitral Annular Calcification and Incident Ischemic Stroke in Treated Hypertensive Patients: The LIFE study. Am J Hypertens. 2013;26(4):567-73.
122. Kruger R, Schutte R, Huisman HW, Hindersson P, Olsen MH, Eugen-Olsen J, Schutte AE. NT-proBNP, C-reactive protein and soluble uPAR in a bi-ethnic male population: the SAfrEIC study. PLoS One. 2013;8(3):e58506.
123. Diederichsen SZ, Gerke O, Olsen MH, Lambrechtsen J, Sand NP, Nørgaard BL, Mickley H, Diederichsen AC. Coronary artery calcification and ECG pattern of left ventricular hypertrophy or strain identify different healthy individuals at risk. J Hypertens. 2013;31(3):595-600.
124. Lyngbæk S, Sehestedt T, Marott JL, Hansen TW, Olsen MH, Andersen O, Linneberg A, Madsbad S, Haugaard SB, Eugen-Olsen J, Jeppesen J. CRP and suPAR are differently related to anthropometry and subclinical organ damage. Int J Cardiol. 2013;167(3):781-5.
125. Hvidt KN, Olsen MH, Holm J-C, Ibsen H. Aortic stiffness in obese children and adolescents: comparison of two distance measures of carotid-femoral pulse wave velocity. Artery Research 2013; 7:186-193.
126. Hvidt KN, Olsen MH, Holm J-C, Ibsen H. Aortic stiffness in obese children and adolescents: the potential bias of a tape distance measurement of carotid-femoral pulse wave velocity. Artery Research 2013;7:234-237.
127. Hvidt KN, Olsen MH, Holm JC, Ibsen H. Obese Children and Adolescents Have Elevated Nighttime Blood Pressure Independent of Insulin Resistance and Arterial Stiffness. Am J Hypertens. 2014 Apr 9.
128. Persu A, Jin Y, Baelen M, Vink E, Verloop WL, Schmidt B, Blicher MK, Severino F, Wuerzner G, Taylor A, Pechère-Bertschi A, Jokhaji F, Fadl Elmula FE, Rosa J,Czarnecka D, Ehret G, Kahan T, Renkin J, Widimsky JI Jr, Jacobs L, Spiering W,Burnier M, Mark PB, Menne J, Olsen MH, Blankestijn PJ, Kjeldsen S, Bots ML,Staessen JA; on behalf of the European Network Coordinating research on Renal Denervation (ENCOReD) Consortium. Eligibility for Renal Denervation: Experience at 11 European Expert Centers. Hypertension 2014;63(6):1319-25.
129. Greve SV, Blicher MK, Blyme A, Sehestedt T, Hansen TW, Rassmusen S, Vishram JK, Ibsen H, Torp-Pedersen C, Olsen MH. Association between albuminuria, atherosclerotic plaques, elevated pulse wave velocity, age, risk category and prognosis in apparently healthy individuals. J Hypertens. 2014;32(5):1034-41.
130. Vishram JK, Borglykke A, Andreasen AH, Jeppesen J, Ibsen H, Jørgensen T, Broda G, Palmieri L, Giampaoli S, Donfrancesco C, Kee F, Mancia G, Cesana G, Kuulasmaa K, Salomaa V, Sans S, Ferrieres J, Tamosiunas A, Söderberg S, McElduff P, Arveiler D, Pajak A, Olsen MH. Do other cardiovascular risk factors influence the impact of age on the association between blood pressure and mortality? The MORGAM Project. J Hypertens. 2014;32(5):1025-33.
131. Kruger R, Rasmussen LM, Argraves WS, Eugen-Olsen J, Nielsen OW, Blyme A, Willenheimer R, Wachtell K, Olsen MH. Extracellular Matrix Biomarker, Fibulin-1, Is Closely Related to NT-proBNP and Soluble Urokinase Plasminogen Activator Receptor in Patients with Aortic Valve Stenosis (The SEAS Study). PLoS One. 2014;9(7):e101522.
132. Hvidt KN, Olsen MH, Ibsen H, Holm JC. Effect of changes in BMI and waist circumference on ambulatory blood pressure in obese children and adolescents. J Hypertens. 2014 Jul;32(7):1470-7.
133. Willeit P, Thompson SG, Agewall S, Bergström G, Bickel H, Catapano AL, Chien KL, de Groot E, Empana JP, Etgen T, Franco OH, Iglseder B, Johnsen SH, Kavousi M,Lind L, Liu J, Mathiesen EB, Norata GD, Olsen MH, Papagianni A, Poppert H, Price JF, Sacco RL, Yanez DN, Zhao D, Schminke U, Bülbül A, Polak JF, Sitzer M, Hofman A, Grigore L, Dörr M, Su TC, Ducimetière P, Xie W, Ronkainen K, Kiechl S, Rundek T, Robertson C, Fagerberg B, Bokemark L, Steinmetz H, Arfan Ikram M, Völzke H,Lin HJ, Plichart M, Tuomainen TP, Desvarieux M, McLachlan S, Schmidt C, Kauhanen J, Willeit J, Lorenz MW, Sander D; for the PROG-IMT study group. Inflammatory markers and extent and progression of early atherosclerosis: Meta-analysis of individual-participant-data from 20 prospective studies of the PROG-IMT collaboration. Eur J Prev Cardiol. 2014 Nov 2, PubMed PMID: 25416041.
134. Hvidt KN, Olsen MH, Holm JC, Ibsen H. Response to the Association Between Obesity and Nighttime Blood Pressure in Obese Children by Adjustments of Insulin Resistance and Arterial Stiffness. Am J Hypertens. 2014 Oct 8, PubMed PMID: 25298175.
135. Nielsen ML, Pareek M, Gerke O, Diederichsen SZ, Greve SV, Blicher MK, Sand NP, Mickley H, Diederichsen AC, Olsen MH. Uncontrolled hypertension is associated with coronary artery calcification and electrocardiographic left ventricular hypertrophy: a case-control study. J Hum Hypertens. 2014 Oct 2, PubMed PMID: 25273860.
136. Vishram JK, Borglykke A, Andreasen AH, Jeppesen J, Ibsen H, Jørgensen T,Palmieri L, Giampaoli S, Donfrancesco C, Kee F, Mancia G, Cesana G, Kuulasmaa K,Salomaa V, Sans S, Ferrieres J, Dallongeville J, Söderberg S, Arveiler D, Wagner A, Tunstall-Pedoe H, Drygas W, Olsen MH; MORGAM Project. Impact of age and gender on the prevalence and prognostic importance of the metabolic syndrome and its components in Europeans. The MORGAM Prospective Cohort Project. PLoS One. 2014;9(9)
137. Sørensen MH, Gerke O, Eugen-Olsen J, Munkholm H, Lambrechtsen J, Sand NP, Mickley H, Rasmussen LM, Olsen MH, Diederichsen A. Soluble urokinase plasminogen activator receptor is in contrast to high-sensitive C-reactive-protein associated with coronary artery calcifications in healthy middle-aged subjects. Atherosclerosis 2014;237(1):60-6.

Abstrakter internationalt (118, hvoraf 50 som 1. forfatter og 10 som sidste forfatter) (kommunikator)
1. Bojsen-Møller F, Olsen MH, Wachtell K. Stressrelaxation and lateral stability of the lumbar spine. Abstract no. 43 at the 6th meeting of European Society of Biomechanics 1988
2. Wachtell K, Ibsen H, Olsen MH, Layborn C, Christoffersen JK, Nørgaard H, Mantoni M, Lund JO. Prevalence of renal artery stenosis in patients with peripheral artery disease and hypertension. Am J Hypertens 1994;7(4 part 2):115A.
3. Olsen MH, Meyer C, Wachtell K, Hove JD, Dige-Petersen H, Rokkedal J, Hesse B, Ibsen H. The importance of changes in conduit and peripheral arteries for coronary flow reserve in patients with hypertension. A LIFE substudy. J Am Coll Cardiol 1999;33(2):279A.
4. Olsen MH, Fossum E, Hjerkinn E, Wachtell K, Høieggen A, Nesbitt SD, Andersen UB, Ibsen H, Kjeldsen SE, Julius S. Vascular hypertrophy and carotid distensibility in patients with hypertension. ICARUS, A LIFE Substudy. J Am Coll Cardiol 1999;33(2):252A.
5. Wachtell K, Olsen MH, Kanters JK, Papademetriou V, Devereus RB, Ibsen H, Rokkedal J. Do non-ischemic hypertensive patients with left ventricular hypertrophy have late potentials or complex ventricular arrhythmias? The LIFE Study. J Am Coll Cardiol 1999;33(2):237A.
6. Olsen MH, Wachtell K, Mulvany MJ, Aalkjaer C, Dige-Petersen H, Rokkedal J, Ibsen H. Severe hypertension is associated with reduced flow-mediated vasodilatation in the brachial artery and thickening of the carotid arteries. A LIFE Substudy. Am J Hypertens 1999;12(4 part 2):177A.
7. Olsen MH, Wachtell K, Aalkjaer C, Mulvany MJ, Dige-Petersen H, Ibsen H. Severe hypertension is associated with reduced endothelial function in resistance arteries independently of metabolic disturbances. A LIFE Substudy. Am J Hypertens 1999;12(4 part 2):178A.
8. Olsen MH, Hermann KL, Dige-Petersen H, Rokkedal J, Ibsen H. In patients with longstanding hypertension exercise capacity is related to cardiovascular remodeling and not insulin sensitivity. A LIFE Substudy. Circulation 1999;100(18):I-179.
9. Olsen MH, Hermann KL, Frandsen E, Dige-Petersen H, Rokkedal J, Roman MJ, Ibsen H. Parallel changes in left ventricular mass and vasodilatory response of the brachial artery wall in patients with longstanding hypertension. A LIFE Substudy. Circulation 1999;100(18):I-176.
10. Olsen MH, Hermann KL, Dige-Petersen H, Rokkedal J, Ibsen H. Influence of blood pressure versus circulating growth factors on cardiovascular remodeling in hypertension. A LIFE Substudy. Circulation 1999;100(18):I-604.
11. Wiinberg N, Bang LE, Wachtell K, Olsen MH, Tuxen C, Rokkedal J, Ibsen H, Devereux RB. 24-hour ambulatory blood pressure in patients with ECG determined left ventricular hypertrophy: The LIFE Study. Am J of Hypertens 1999;12(4 part 2):34A.
12. Bang LE, Wiinberg N, Wachtell K, Olsen MH, Tuxen C, Rokkedal J, Ibsen H, Devereux RB. White coat hypertension in patients with ECG determined left ventricular hypertrophy: The LIFE Study. Am J Hypertens 1999;12(4 part 2):163A.
13. Wachtell K, Palmieri V, Devereux RB, Olsen MH, Papademetriou V, Niemen MS, Smith G, Dahlöf B. Changes in systolic function and midwall mechanics after one year of antihypertensive treatment. The LIFE Study. J Am Coll Cardiol 2000;35:249A.
14. Wachtell K, Tuxen C, Hermann KL, Hansen TF, Olsen MH, Palmieri V, Hildebrandt P, Papademetriou V, Bella JN, Rokkedal J, Devereux RB. Relations between echocardiographic and magnetic resonance imaging in hypertensive patients with electrocardiographic left ventricular hypertrophy. The LIFE Study. J Am Coll Cardiol 2000;35:453A.
15. Wachtell K, Palmieri V, Olsen MH, Bella JN, Aalto T, Dahlöf B, Gerdts E, Borch-Johnsen K, Rokkedal J, Ibsen H, Devereux RB. Parallel cardiac and renal damage in patients with left ventricular hypertrophy. The LIFE Study. J Am Coll Cardiol 2000;35:321A.
16. Wachtell K, Palmieri V, Olsen MH, Gerdts E, Bella JN, Aalto T, Devereux RB. Structural and functional left ventricular relations to obesity in hypertensive patients with electrocardiographic left ventricular hypertrophy. The LIFE Study. Circulation 2000;102:II-607.
17. Olsen MH, Wachtell K, Meyer C, Hermann KL, Dige-Petersen H, Rokkedal J, Ibsen H. Are cardiovascular changes in longstanding hypertension solely blood pressure dependent? A LIFE substudy. J Hypertens 2000;18:S185.
18. Wachtell K, Olsen MH, Dahlöf B, Devereux RB, Kjeldsen SE, Nieminen MS, Okin PM, Papademetriou V, Mogensen CE, Borch-Johnsen K, Ibsen H. Microalbuminuria in hypertensive patients with electrocardiographic left ventricular hypertrophy. The LIFE Study. J Hypertens 2000;18:S103.
19. Olsen MH, Wachtell K, Meyer C, Hermann KL, Dige-Petersen H, Rokkedal J, Ibsen H. Are cardiovascular changes in longstanding hypertension solely blood pressure dependent? A LIFE substudy. J Hypertens 2000;18:S34.
20. Olsen MH, Wachtell K, Hjerkinn E, Høieggen A, Fossum E, Rokkedal J, Smith G, Devereux RB, Ibsen H, Kjeldsen SE, Julius S. Parallel cardiovascular and renal glomerular abnormalities in longstanding hypertension. A LIFE substudy. J Hypertens 2000;18:S36.
21. Wachtell K, Olsen MH, Dahlöf B, Devereux RB, Kjeldsen SE, Nieminen MS, Okin PM, Papademetriou V, Mogensen CE, Borch-Johnsen K, Ibsen H. Microalbuminuria in hypertensive patients with electrocardiographic left ventricular hypertrophy. The LIFE Study. Circulation 2000;102:II-696.
22. Olsen MH, Wachtell K, Okin PM, Kjeldsen SE, Dahlöf B, Borch-Johnsen K, Devereux RB, Ibsen H. Relationships between albuminuria, left ventricular hypertrophy and blood pressure after one year of anti-hypertensive treatment. The LIFE Study. J Am Coll Cardiol 2001;37:261A.

23. Olsen MH, Wachtell K, Bella JN, Palmieri V, Gerdts E, Nieminen MS, Smith G, Dahlöf B, Ibsen H, Devereux RB. Aortic Valve Sclerosis, Hemodynamics and Cardiovascular Risk in Hypertension. A LIFE Substudy. J Am Coll Cardiol 2002;39(5A):1036M-129 (moderated poster-session).
24. Olsen MH, Hjerkinn E, Wachtell K, Høieggen A, Bella JN, Nesbitt SD, Fossum E, Kjeldsen SE, Devereux RB, Julius S, Ibsen H. Are Left Ventricular Mass, Geometry and Function Related to Vascular Changes and/or Insulin Resistance in Longstanding Hypertension. A LIFE Substudy. J Am Coll Cardiol 2002;39:255A.
25. Olsen MH, Wachtell K, Tuxen C, Fossum E, Bang LE, Wiinberg N, Devereux RB, Ibsen H. Collagen Synthesis is Related to Blood Pressure Rather than Left Ventricular Mass. A LIFE Substudy. J Am Coll Cardiol 2002;39:215B (oral presentation).
26. Olsen MH, Wachtell K, Tuxen C, Høieggen A, Bang LE, Wiinberg N, Ibsen H, Rokkedal J. Effect of Losartan versus Atenolol on Collagen Synthesis in Hypertension. A LIFE Substudy. J Am Coll Cardiol 2002;39:173B.
27. Olsen MH, Wachtell K, Bang LE, Rokkedal J, Frandsen E, Devereux RB, Ibsen H, Dige-Petersen H. Sub-acute Changes in Circulating Collagen Markers During Anti-Hypertensive Treatment. A LIFE Substudy. J Am Coll Cardiol 2002;39:343B (oral presentation).
28. Wachtell K, Olsen MH, Dahlöf B, Devereux RB, Kjeldsen SE, Nieminen MS, Julius S, Okin PM, Borch-Johnsen K, Ibsen H. Is urinary albumin excretion and left ventricular hypertrophy both independent predictors of overall mortality in patients with electrocardiographic left ventricular hypertrophy? J Am Coll Cardiol 2002; 39:237A.
29. Wachtell K, Olsen MH, Dahlöf B, Devereux RB, Kjeldsen SE, Nieminen MS, Okin PM, Borch-Johnsen K, Ibsen H. Does losartan treated patients with albuminuria have better cardiovascular outcome than those treated with atenolol? The LIFE study. Am J Hypertens 2002;15:21A.
30. Olsen MH, Hjerkinn E, Wachtell K, Høieggen A, Fossum E, Nesbitt SD, Dige-Petersen H, Kjeldsen SE, Julius S, Ibsen H. The Effect of Losartan versus Atenolol on Insulin Sensitivity and Vascular Structure in Essential Hypertension. ICARUS, a LIFE Substudy. J Hypertens 2002;20:S165.
31. Olsen MH, Wachtell K, Tuxen C, Fossum E, Bang LE, Wiinberg N, Hjerkinn E, Rokkedal J, Devereux RB, Ibsen H. Dynamics of Collagen Synthesis in Hypertension - Blood Pressure or Treatment Dependent. A LIFE Substudy. J Hypertens 2002;20:S10 (oral presentation).
32. Olsen MH, Fossum E, Wachtell K, Høieggen A, Hjerkinn E, Kjeldsen SE, Dige-Petersen H, Julius S, Ibsen H. The Effect of Losartan versus Atenolol on Insulin Sensitivity and Vascular Structure in Essential Hypertension. ICARUS, a LIFE Substudy. Circulation 2002;106:II-574.
33. Olsen MH, Wachtell K, Neland K, Rokkedal J, Ibsen H, Dige-Petersen H. The Effect of Losartan versus Atenolol on Carotid Artery Hypertrophy in Essential Hypertension. A LIFE Substudy. Circulation 2002;106:II-574.
34. Lindholm LH, Ibsen H, Borch-Johnsen K, Olsen MH, Wachtell K, Dahlöf B, Devereux RB, Beevers G, de Faire U, Fyhrquist F, Julius S, Kjeldsen SE, Kristianson K, Lederballe-Pedersen O, Nieminen MS, Omvik P, Oparil S, Wedel H, Aurup P, Edelman J. New-onset diabetes in the losartan intervention for endpoint reduction in hypertension study (LIFE). Circulation 2002;106:II-573.
35. Wachtell K, Gerdts E, Palmieri V, Olsen MH, Nieminen MS, Papademetriou V, Rokkedal J, Aurigemma GP, Devereux RB. Endocardial as well as midwall fractional shortening predict cardiovascular outcome in hypertension. The LIFE Study. Circulation 2002;106:II-687.
36. Olsen MH, Wachtell K, Bella JN, Boman K, Gerdts E, Papademetriou V, Nieminen MS, Rokkedal J, Dahlöf B, Devereux RB. The Effect of Losartan versus Atenolol on Aortic Valve Sclerosis. A LIFE Substudy. J Am Coll Cardiol 2003;41:505A (moderated poster-session).
37. Olsen MH, Wachtell K, Bella JN, Palmieri V, Gerdts E, Nieminen MS, Smith G, Dahlöf B, Ibsen H, Devereux RB. Does Aortic Valve Sclerosis add to Cardiovascular Risk independently of Albuminuria in Hypertension? A LIFE Substudy. J Am Coll Cardiol 2003;41:510A (oral presentation).
38. Olsen MH, Wachtell K, Tuxen C, Fossum E, Bang L, Hall C, Ibsen H, Rokkedal J, Devereux RB, Hildebrandt P. N-terminal proBrain Natriuretic Peptide Predict Cardiovascular Events in Patients with Hypertension and Left Ventricular Hypertrophy. A LIFE Study. J Am Coll Cardiol 2003;41:276A.
39. Olsen MH, Wachtell K, Bella JN, Palmieri V, Gerdts E, Nieminen MS, Smith G, Dahlöf B, Ibsen H, Devereux RB. Is Albuminuria a Cardiovascular Risk Factor Independent of Left Ventricular Hypertrophy in Hypertension? A LIFE Substudy. J Am Coll Cardiol 2003;41:229A.
40. Wachtell K, Olsen MH, Tuxen C, Bang L, Hall C, Hildebrandt P, Ibsen H, Rokkedal J, Devereux RB. Are NT-pro brain natriuretic peptides related to systolic and diastolic left ventricular function at baseline and during antihypertensive treatment? A LIFE Study. J Am Coll Cardiol 2003;41:148A.
41. Wachtell K, Olsen MH, Tuxen C, Bang LE, Hall C, Hildebrandt PR, Ibsen H, Rokkedal J, Devereux RB. Is NT-pro Brain Natriuretic Peptide Related to Left Ventricular Mass as Well as Wall Stress? The LIFE Study. Am J Hypertens 2003;16:92A
42. Papademetriou V, Wachtell K, Gerdts E, Narayan P, Palmieri V, Olsen MH, Dahlöf B, Devereux RB. Left Ventricular Changes in Patients with Isolated Systolic or Combined Hypertension and Echocardiographic Left Ventricular Hypertrophy: The LIFE Study. Am J Hypertens 2003;16:126A.
43. Franklin SS, Wachtell K, Papademetriou V, Olsen MH, Ibsen H, Kjeldsen SE, Devereux RB, Julius S, Dahlöf B. Effect of Losartan Compared to Atenolol on Cardiovascular Mortality and Morbidity in High and Low Risk Patients with Left Ventricular Hypertrophy. A Losartan Intervention For Endpoint reduction – The LIFE study. J Hypertens 2003;21(Suppl 4):S67.

44. Ibsen H, Olsen MH, Wachtell K, Borch-Johnsen K, Lindholm L, Dahlof B, Snapinn S. Does Albuminuria Predict Cardiovascular Outcome on Treatment with Losartan Versus Atenolol in Patients with Hypertension and Left Ventricular Hypertrophy? The LIFE study. J Hypertens 2003;21(Suppl 4):S68.
45. Ibsen H, Olsen MH, Wachtell K, Borch-Johnsen K, Lindholm L, Dahlof B, Snapinn S. Reduction in Urinary Albumin/creatinine Ratio During Antihypertensive Treatment Translates to Reduced Risk for Cardiovascular Complications. The LIFE study. J Hypertens 2003;21(Suppl 4):S225.
46. Olsen MH, Wachtell K, Ibsen H, Lindholm L, Dahlöf B, Devereux R, Julius S, Kjeldsen S, Nieminen M, Okin P. Treatment Induced Reductions in Albuminuria and in Electrocardiographic Left Ventricular Hypertrophy Independently Improves Prognosis in Hypertension. The LIFE study. J Hypertens 2003;21(Suppl 4):S67.
47. Wachtell K, Lehto M, Hornestam BCR, Gerdts E, Olsen MH, Kjeldsen SE, Lindholm LH, Dahlöf B. Losartan Reduces the Risk of New-onset Atrial Fibrillation in Hypertensive Patients with ECG Left Ventricular Hypertrophy: the LIFE Study. Eur Heart J 2003;24:S504.
48. Olsen MH, Wachtell K, Ibsen H, Bella JN, Dahlöf B, Gerdts E, Nieminen MS, Devereux RB. Reductions in Albuminuria and Echocardiographic Left Ventricular Hypertrophy Independently Improves Prognosis in Hypertension. The LIFE study. Eur Heart J 2003;24:S579.
49. Olsen MH, Wachtell K, Tuxen C, Fossum E, Hall C, Ibsen H, Devereux RB, Hildebrandt PR. Opposite Effects of Losartan and Atenolol on Natriuretic Peptides in Patients with Hypertension and Left Ventricular Hypertrophy. A LIFE Study. Eur Heart J 2003;24:S580.
50. Franklin SS, Wachtell K, Papademetriou V, Olsen MH, Fyhrquist F, Ibsen H, Julius S, Kjeldsen SE, Dahlöf B. Effect of Losartan Compared to Atenolol on Cardiovascular Mortality and Morbidity in High- and Low-Risk Patients with Hypertension and Left Ventricular Hypertrophy—the LIFE study. Circulation 2003; 108:IV-764.
51. Boesen M, Grønning BA, Hermann KL, Olsen MH, Wachtell K, Pedersen F, Hall C, Hildebrandt PR. N-Terminal Pro Brain Natriuretic Peptide is Related to Left Ventricular Mass in Hypertensive Patients with Preserved Systolic Function – An MR substudy of the LIFE Study. Circulation 2003; 108:IV-452.
52. Ibsen H, Olsen MH, Wachtell K, Borch-Johsen K, Lindholm LH, Dahlöf B, Snapinn SM. Albuminuria Predicts Cardiovascular Outcome on Treatment With Losartan Versus Atenolol in Patients With Diabetes, Hypertension and Left Ventricular Hypertrophy? A LIFE Diabetes Substudy. J Hypertens 2004;22:S64.
53. Wachtell K, Devereux RB, Snapinn SM, Olsen MH, de Faire U, Ibsen H, Julius S, Kjeldsen SE, Lindholm LH, Nieminen MS, Dahlöf B. Does Hormones Replacement Therapy in Women Influence Their Benefit of Losartan-treatment in the LIFE Study? J Hypertens 2004; 22: S114.

54. Wachtell K, Palmieri V, Gerdts E, Bella JN, Nieminen MS, Olsen MH, Poulsen SH, Ärnlöf J, Papademetriou V, Dahlöf B, Devereux RB. Myocardial Performance Index Independently Predicts Cardiovascular Morbidity and Mortality in Hypertensive Patients with Electrocardiographic Left Ventricular Hypertrophy: The LIFE study. J Am Coll Cardiol 2004;43:227A.
55. Olsen MH, Clausen P , Wachtell K, Andersen U, Neland K, Ibsen H, Dige-Petersen H, The Effect of Losartan vs. Atenolol on Circulating Adhesion Molecules in Essential Hypertension. ALIFE Substudy. J Am Coll Cardiol 2004;43:445A.
56. Wachtell K, Devereux RB, Snapinn SM, Olsen MH, de Faire U, Ibsen H, Julius S, Kjeldsen SE, Lindholm LH, Nieminen MS, Dahlöf B. Does Hormones Replacement Therapy in Women Influence Their Benefit of Losartan-treatment in the LIFE Study? J Am Coll Cardiol 2004;43:482A.
57. Boman KO Sr, Olsen MH, Wachtell K, Olofsson M, Ibsen H, Dige-Petersen H, Nilsson K. The Effect of Losartan Versus Atenolol on Hemostasis and Fibrinolysis in Hypertensive Patients with Left Ventricular Hypertrophy: A LIFE Substudy. J Am Coll Cardiol 2004;43:482A.
58. Olsen MH, Wachtell K, Hall C, Ibsen H, Rokkedal J, Kjeldsen SE, Julius S, Devereux RB, Dahlöf B, Hildebrandt PR. N-terminal pro Brain Natriuretic Peptide Predicts Cardiovascular Events in Patients with Hypertension and Left Ventricular Hypertrophy. A LIFE Study. J Am Coll Cardiol 2004;43:530A. (oral presentation)
59. Wachtell K, Olsen MH, Devereux RB, Ibsen H, Kjeldsen SE, Julius S, Lindholm LH, Nieminen MS, Dahlöf B. Does Left Ventricular Hypertrophy Predict Sudden Cardiac Death Independent of Ischemia? The LIFE Study. J Am Coll Cardiol 2004;43:530A.
60. Ibsen H, Olsen MH, Wachtell K, Borch-Johnsen K, Lindholm LH, Dahlöf B, Snapinn SM. Albuminuria Predicts Cardiovascular Outcome with Losartan Versus Atenolol in Patients with Diabetes, Hypertension and Left Ventricular Hypertrophy. A LIFE Diabetes Substudy. Am J Hyper 2004;17:2A
61. Fossum E, Olsen MH, Høiggen A, Wachtell K, Reims HM, Ibsen H, Julius S, Kjeldsen SE. Long-term Plasma Catecholamine Levels in Patients With Hypertension and Left Ventricular Hypertrophy Treated With Losartan or Atenolol. ICARUS, a LIFE Substudy. Am J Hyper 2004;17:106A.
62. Høieggen A, Fossum E, Olsen MH, Wachtell K, Hjerkinn E, Devereux RB, Ibsen H, Kjeldsen SE. The Effect of Losartan Versus Atenolol on Carotid Atherosclerosis in the Common Carotid Arteries in Hypertension. ICARUS a LIFE Substudy. Am J Hypertens 2004;17:111A.
63. Wiinberg N, Bang LE, Wachtell K, Larsen J, Tuxen C, Olsen MH, Ibsen H, Hildebrandt PR. Effect of Atenolol and Losartan on 24-Hour Ambulatory Blood Pressure in Patients with Hypertension: A LIFE Substudy. Am J Hypertens 2004;17:187A.
64. Bang LB, Wiinberg N, Wachtell K, Larsen J, Tuxen C, Olsen MH, Ibsen H, Hildebrandt PR. Effect of atenolol and losartan on 24-hour ambulatory blood pressure in a subgroup of LIFE patients. J Hypertens 2004;22(Suppl 2):S112.
65. Fossum E, Olsen MH, Hoieggen A, Wachtell K, Reims HM, Ibsen H, Julius S, Kjeldsen SE. Long-term plasma catecholamines in patients with hypertension and left ventricular hypertrophy treated with losartan or atenolol. ICARUS, a LIFE substudy. J Hypertens 2004;22(Suppl 2):S46.
66. Olsen MH, Hansen TW, Christensen MK, Gustafsson F, Rasmussen S, Wachtell K, Borch-Johnsen K, Ibsen H, Jørgensen T, Hildebrandt PR. High Sensitive CRP and Urine Albumin/creatinine Ratio Are Only Weakly Related in the General Population Reflecting Different Aspects of Cardiovascular Damage. Eur Heart J 2004
67. Olsen MH, Wachtell K, Beevers G, Dahlöf B, de Faire U, Fyhrquist F, Ibsen H, Julius S, Kjeldsen SE, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H. Does Losartan Reduce the Incidence of Coronary Revascularization in Patients with Hypertension and Electrocardiographic Left Ventricular Hypertrophy? The LIFE Study. Eur Heart J 2004
68. Okin PM, Wachtell K, Nieminen MS, Oikarinen L, Viitasalo M, Toivonen L, Ibsen H, Olsen MH, Borch-Johnsen K, Lindholm LH, Kjeldsen SE, Dahlöf B. Electrocardiographic Strain Pattern and Albuminuria Additively Predict Outcomes in Hypertensive Patients: The LIFE Study. Circulation 2004;110:III-730.
69. Wachtell K, Gerdts E, Palmieri V, Bella JN, Olsen MH, Rokkedal J, Boman K, Smith G, Dahlöf B, Devereux RB. Does Losartan Improve Diastolic Left Ventricular Function Better than Atenolol? Circulation 2004;110:III-637.
70. Olsen MH, Wachtell K, Hall C, Ibsen H, Rokkedal J, Kjeldsen SE, Devereux RB, Dahlöf B, Hildebrandt PR. Does High Sensitive C-Reactive Protein Provide Additional Prognostic Information in Patients with Hypertension and Left Ventricular Hypertrophy? A LIFE Study. Circulation 2004;110:III-731.
71. Olsen MH, Wachtell K, Beevers G, Dahlöf B, Devereux RB, de Faire U, Fyhrquist F, Ibsen H, Julius S, Kjeldsen SE, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H. Losartan Has Positive Effects on Lipid Metabolism Compared to Atenolol in Patients with Hypertension and Electrocardiographic Left Ventricular Hypertrophy. The LIFE Study. J Am Coll Cardiol 2005;45:423A.
72. Olsen MH, Wachtell K, Neland K, Rokkedal J, Ibsen H, Dige-Petersen H. The Effect of Losartan versus Atenolol on Brachial Artery Vasodilatory Capacity and Hypertrophy in Essential Hypertension. A LIFE Substudy. J Am Coll Cardiol 2005;45:441A. (oral presentation)
73. Tuxen C, Wiinberg N, Olsen MH, Wachtell K, Hildebrandt PR, Mehlsen J. Brachial Artery Compliance, Neurohormones and Vascular Collagen in Hypertension Accompanied by Left Ventricular Hypertrophy. A LIFE Study. Am J Hypertens 2005;18:P-37.
74. Wachtell K, Palmieri V, Gerdts E, Olsen MH, Nieminen MS, Boman K, Papademetriou V, Rokkedal J, Dahlöf B, Devereux RB. Echocardiographic determinants of new-onset atrial fibrillation in patients with hypertension and left ventricular hypertrophy: The LIFE study. J Am Coll Cardiol 2005;45:374A.

75. Okin PM, Wachtell K, Devereux RB, Nieminen MS, Oikarinen L, Viitasalo M, Toivonen L, Ibsen H, Olsen MH, Borch-Johnsen K, Lindholm LH, Kjeldsen SE, Dahlof B. Electrocardiographic strain pattern and albuminuria additively predict new-onset congestive heart failure in hypertensive patients: the LIFE study. J Am Coll Cardiol 2005;45:373A.
76. Olsen MH, Wachtell K, Aalkjær C, Mulvany M, Rokkedal J, Dige-Petersen H, Ibsen H. The Effect of Losartan versus Atenolol on Structure and Function´in Subcutaneous Small Arteries in Essential Hypertension. A LIFE Substudy. European Heart J 2005; moderated poster P2206
77. Olsen MH, Hansen TW, Christensen MK, Gustafsson F, Wachtell K, Borch-Johnsen K, Jørgensen T, Hildebrandt P. N-terminal pro brain natriuretic peptide is inversely related to metabolic cardiovascular risk factors – a paradoxical relationship to the metabolic syndrome. European Heart J 2005; oral presentation 2032
78. Olsen MH, Hansen TW, Christensen MK, Gustafsson F, Wachtell K, Borch-Johnsen K, Jørgensen T, Hildebrandt P. N-terminal pro brain natriuretic peptide and urine albumin/creatinine ratio, but not high sensitivity C-reactive protein predicts cardiovascular death in the general population after adjustment for traditional risk factors. European Heart J 2005; oral presentation 2686
79. Olsen MH, Wachtell K, Beevers G, Dahlöf B, Devereux RB, de Faire U, Fyhrquist F, Ibsen H, Kjeldsen SE, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H. In patients with hypertension and electrocardiographic left ventricular hypertrophy, high hemoglobin was associated with cardiovascular events, low hemoglobin with all-cause mortality, and large fall in hemoglobin with both. The LIFE Study. J Am Coll Cardiol 2006; 47(4) Suppl. A: 361A oral presentation (848-5)
80. Olsen MH, Wachtell K, Dahlöf B, Devereux RB, Ibsen H, Kjeldsen SE, Lindholm LH, Nieminen MS. Losartan- versus atenolol-based antihypertensive treatment reduces cardiovascular events especially in elderly patients with hypertension and electrocardiographic left ventricular hypertrophy. The LIFE Study. European Heart J 2006; 27(Suppl.): 667, P3997
81. Olsen MH, Hansen TV, Christensen MK, Gustafsson F, Rasmussen S, Wachtell K, Borch-Johnsen K, Ibsen H, Torp-Pedersen C, Jørgensen T, Hildebrandt P. The impact of age and gender on the prognostic importance of N-terminal pro brain natriuretic peptide, high sensitivity C-reactive protein and urine albumin/creatinine ratio in apparently healthy individuals. European Heart J 2006; 27(Suppl.): 249, P1555
82. Olsen MH, Hansen TV, Christensen MK, Gustafsson F, Rasmussen S, Wachtell K, Borch-Johnsen K, Ibsen H, Torp-Pedersen C, Jørgensen T, Hildebrandt P. By which mechanism does N-terminal pro brain natriuretic peptide predict cardiovascular outcome in the general population? European Heart J 2006; 27(Suppl.): 210, P1394
83. Olsen MH, Hansen TV, Christensen MK, Gustafsson F, Rasmussen S, Wachtell K, Borch-Johnsen K, Ibsen H, Torp-Pedersen C, Jørgensen T, Hildebrandt P. The impact of obesity on the prognostic importance of N-terminal pro brain natriuretic peptide, high sensitivity C-reactive protein and urine albumin/creatinine ratio in apparently healthy people. European Heart J 2006; 27(Suppl.): 938, P5366

84. Olsen MH, Hansen TV, Christensen MK, Gustafsson F, Rasmussen S, Wachtell K, Borch-Johnsen K, Ibsen H, Torp-Pedersen C, Jørgensen T, Hildebrandt P. High sensitivity C-reactive protein improves cardiovascular risk prediction in low risk subjects and N-terminal pro brain natriuretic peptide in moderate-high risk subjects. European Heart J 2006; 27(Suppl.): 48, P503
85. Wachtell K, Gerdts E, Aurigemma G, Boman K, Dahlöf B, Kjeldsen SE, Lindholm LH, Nieminen MS, Olsen MH, Palmieri V, Papademetriou V, Rokkedal J, Devereux RB. Does Reduction in Left Atrial Diameter During Antihypertensive Treatment Reduce New-Onset Atrial Fibrillation in Hypertensive Patients with Left Ventricular Hypertrophy: The LIFE Study. J Am Coll Card 2006;47:9A
86. de Simone G, Olsen MH, Wachtell K, Hille DA, Dahlof B, Ibsen H, Kjeldsen SE, Lyle PA, Devereux RB. Metabolic Syndrome Predicts Higher Cardiovascular Risk Independently of Electrocardiographic Left Ventricular Hypertrophy: The LIFE Study. J Am Coll Card 2006;47:361A.
87. Wachtell K, Gerdts E, Cramariuc D, Olsen MH, Egstrup K, Willenheimer R, Gohlke-Bärwolf C, Ray S. Systolic Left Ventricular Function in Patients with Asymptomatic and Mild Aortic Stenosis: The SEAS Study. Eur Heart J 2006;27:980.
88. Wachtell K, Chinally M, Olsen MH, de Simone, Gerdts E, Nieminen MS, Dahlöf B, Devereux RB. Losartan Preserves Left Atrial Systolic Force Better Than Atenolol, and may Contribute to Lower Incidence of New-onset Atrial Fibrillation: The LIFE study. Circulation 2006;114:791 (suppl II).
89. Olsen MH, Wachtell K, Hall C, Ibsen H, Rokkedal J, Kjeldsen SE, Devereux RB, Dahlöf B, Hildebrandt PR. Is the prognogstic value of N-terminal pro-brain natriuretic peptide and high sensitivity C-reactive protein independent of subclinical and clinical cardiovascular disease? A LIFE Study. J Hypertens 2007; 25(Suppl.2): S140, oral presentation 4C.3
90. Olsen MH, Hansen TW, Gustafsson F, Rasmussen S, Borch-Johnsen K, Ibsen H, Torp-Pedersen C, Jørgensen T, Hildebrandt PR. Cut-off values for clinical use of N-terminal pro brain natriuretic peptide, high sensitivity C-reactive protein and urine albumin/creatinine ratio in the general population. J Hypertens 2007; 25(Suppl.2): S215, P23.213
91. Li Z, Kjeldsen SE, Julius S, Olsen MH, Wachtell K, Ibsen H, Gerdts E, Nieminen MS, Jern S, Okin PM, Dahlöf B, Devereux RB: Prevalence and Correlates of Mitral Annular Calcification in Hypertensive Adults With Left Ventricular Hypertrophy: The LIFE Study. J Am Coll Cardiol 2007; 49(Suppl A):332A.
92. de Simone G, Okin PM, Gerdts E, Olsen MH, Wachtell K, Hille DA, Lyle PA, Kjeldsen SE, Devereux RB. Does Metabolic Syndrome Influence Reduction of ECG Left Ventricular Hypertrophy? The LIFE study. J Hypertens 2007;25(suppl 2):S78.
93. Li Z, Wachtell K, Julius S, Olsen MH, Ibsen H, Gerdts E, Nieminen MS, Jern S, Okin PM, Dahlöf B, Devereux RB. Association of Aortic Regurgitation with Cardiovascular Morbidity and Mortality in Hypertensive Patients with Left Ventricular Hypertrophy: the LIFE study. Circulation 2007;116(Suppl II):II-735.

94. Li Z, Wachtell K, Julius S, Olsen MH, Ibsen H, Gerdts E, Nieminen MS, Jern S, Okin PM, Dahlöf B, Devereux RB. Gender Difference in the Association of Aortic Valve Sclerosis and Cardiovascular Events in Hypertensive Adults with Left Ventricular Hypertrophy: the LIFE study. Circulation 2007;116(Suppl II):II-735.
95. Sehestedt T, Jeppesen J, Hansen TW, Christensen MK, Rasmussen S, Wachtell K, Ibsen H, Torp-Pedersen C, Jørgensen T, Olsen MH. Which markers of subclinical cardiovascular damage to measure in subjects with high normal blood pressure? J Hypertens 2008;26(Suppl.1):OS5
96. Sehestedt T, Jeppesen J, Hansen TW, Christensen MK, Rasmussen S, Wachtell K, Ibsen H, Torp-Pedersen C, Jørgensen T, Olsen MH. The risk chart from European Society of Hypertension and HeartScore predicted cardiovascular risk equally well in the general population. J Hypertens 2008;26(Suppl.1):OS14
97. Olsen MH, Sehestedt T, Wachtell K, Dahlöf B, Devereux RB, Ibsen H, Kjeldsen SE, Lindholm LH, Nieminen MS. Possible explanations for why losartan- versus atenolol-based antihypertensive treatment reduced cardiovascular events especially well in elderly patients the LIFE study. J Hypertens 2008;26(Suppl.1):OS27
98. Larstorp ACK, Wachtell K, Olsen MH, Jern S, Okin PM, Devereux RB, Ibsen H, Dahlöf B, Kjeldsen SE. Regression of Left Ventricular Hypertrophy in Patients With Isolated Systolic Hypertension. The LIFE study. J Hypertens 2008;26(Suppl.1): PS17.56
99. Olsen MH, Sehestedt T, Jeppesen J, Hansen TW, Christensen MK, Borch-Johnsen K, Ibsen H, Torp-Pedersen C, Jørgensen T, Hildebrandt PR. Markers of subclinical vascular damage may improve HeartScore risk stratification and reduce the number of candidates for primary prevention. European Heart J 2008;29(Suppl.): P1419
100. Olsen MH, Eugen-Olsen J, Jeppesen J, Andersen O, Hansen TW, Linneberg A, Christensen MK, Ibsen H, Jørgensen T, Haugaard SB. The new inflammatory marker soluble urokinase plasminogen activator receptor is associated with atherosclerosis independently of traditional cardiovascular risk factors. European Heart J 2008;29(Suppl.): P3657
101. Olsen MH, Eugen-Olsen J, Jeppesen J, Andersen O, Hansen TW, Linneberg A, Christensen MK, Ibsen H, Jørgensen T, Haugaard SB. The new inflammatory marker soluble urokinase plasminogen activator receptor is associated with increased cardiovascular risk independently of subclinical vascular damage. European Heart J 2008;29(Suppl.): P3658
102. Wachtell K, Olsen MH, Bella JN, Gerdts E, Boman K, Nieminen MS, Omvik P, Dahlöf B, Devereux RB. Afterload Reduction with Losartan Increases Cardiac Output more than Heart Rate Reduction with Atenolol: The LIFE study. Eur Heart J 2008 In press.
103. Sehested TSG, Vishram JKK, Lyngbæk S, Sehestedt T,Jeppesen J, Hansen TW, Borch-Johnsen K, Ibsen H, Hildebrandt PR, Torp-Petersen C, Jørgensen T, Olsen MH. Metabolic risk factors predict cardiovascular events in midlle aged, but not in elderly subjects – Influence of aging on inflammation and atherosclerosis? J Hypertens 2009;27(suppl 4): S323, 7D.8 (oral presentation).
104. Olsen MH, Wachtell K, Ibsen H, Lindholm LH, Kjeldsen SE, Omvik P, Nieminen MS, Dahlöf B, Okin PM, Devereux RB. Importance of subclinical cardiovascular damage in assessing cardiovascular risk reduction during antihypertensive treatment. A LIFE substudy. J Hypertens 2009;27(suppl 4): S178, 6A.1 (oral presentation).
105. Søraas CL, Wachtell K, Okin PM, Dahlöf B, Kjeldsen SE, Devereux RB, Olsen MH. Lack of regression of left ventricular hypertrophy is associated with higher incidence of revascularization in hypertension. The LIFE Study. J Hypertens 2009;27(suppl 4): S317, 7B.12 (oral presentation).
106. Larstorp ACK, Wachtell K, Olsen MH, Jern S, Okin PM, Devereux RB, Ibsen H, Dahlof B, Kjeldsen SE. Systolic blood pressure reduction during antihypertensive therapy and the prediction of new-onset atrial fibrillation in patients with isolated systolic hypertension. The LIFE study. J Hypertens 2009;27(suppl 4): S172, 7B.11 (oral presentation).
107. Wiik BP, Larstorp ACK, Høieggen A, Kjeldsen SE, Olsen MH, Wachtell K, Ibsen H, Lindholm LH, Dahlöf B, Devereux RB, Okin PM. Serum uric acid predicts new-onset diabetes in hypertensive patients with left ventricular hypertrophy: The LIFE Study. J Hypertens 2009;27(suppl 4): S172, 5B.5 (oral presentation).
108. Sehestedt T, Jeppesen J, Hansen TW, Rasmussen S, Wachtell K, Ibsen H, Torp-Pedersen C, Olsen MH. The role of subclinical organ damage for cardiovascular risk stratification. J Hypertens 2009;27(suppl 4): S172, 5B.5 (oral presentation).
109. Ariansen I, Larstorp AC, Wachtell K, Olsen MH, Ibsen H, Devereux RB, Okin PM, Kjeldsen SE, LIFE Study Group. Association of pulse pressure with new-onset atrial fibrillation in hypertensive patients with ECG left ventricular hypertrophy: the LIFE study. Eur Heart J 2009;Vol.30(Abstract Supplement):144
110. Ariansen I, Wachtell K, Olsen MH, Ibsen H, Devereux RB, Okin PM, Kjeldsen SE, Dahlof B, LIFE Study Group.Impact of alcohol and smoking habits on the risk of new-onset atrial fibrillation in hypertensive patients with ecg left ventricular hypertrophy: the life study. Eur Heart J 2009;Vol.30(Abstract Supplement):160
111. Vishram JKK, Sehestedt T, Sehested TSG, Lyngbæk S, Jeppesen J, Hansen TW, Torp-Pedersen C, Olsen MH. Total/high density lipoprotein cholesterol ratio improves prediction of cardiovascular death by SCORE in men, but not in women –
improved prediction of ischemic heart disease, but not of stroke. Eur J Cardiovasc Prev Rehabil. 2010
112. Vishram JKK, Sehestedt T, Sehested TSG, Lyngbæk S, Jeppesen J, Hansen TW, Torp-Pedersen C, Olsen MH. Total/high density lipoprotein cholesterol ratio improves prediction of cardiovascular death by SCORE in men, but not in women –
improved prediction of ischemic heart disease, but not of stroke. J Hypertens 2010;28(e-Suppl. A):334 (oral).
113. Søraas CL, Wachtell K, Okin PM, Dahlöf B, Kjeldsen SE, Devereux RB, Olsen MH. Lack of regression of left ventriculsr hypertrophy is associated with cardiovascular mortality after revascularization in hypertensives. The LIFE study. J Hypertens 2010;28(e-Suppl. A):e409 (oral).

114. Vishram JKK, Wachtell K, Ibsen H, Lindholm L, Kjeldsen SE, Dahlöf B, Okin PM, Devereux RB, Olsen MH. The importance of blood pressure variability for subclinical organ damage and cardiovascular events. A LIFE substudy. J Hypertens 2010;28 (e-Suppl. A):e425 (oral).
115. Sehestedt T, Eugen-Olsen J, Jeppesen J, Andersen O, Hansen TW, Linneberg A, Jørgensen T, Haugaard SB, Ibsen H, Torp-Pedersen C, Olsen MH., Risk Prediction with Markers of Subclinical Damage in subjects with a History of Cardiovascular Disease. J Hypertens. 2010;28(e-Suppl. A): Page 119.
116. Larstorp AC, Olsen MH, Okin PM, Devereux RB, Ibsen H, Dahlöf B, Kjeldsen SE, Wachtell K. Reduced ECG-LVH during antihypertensive therapy is associated with less hospitalization for heart failure in patients with isloated systolic hypertension. The LIFE Study. J Hypertens. 2010:28(e-Suppl. A):e1 (oral)
117. Vishram JKK, Ibsen H, Borglykke A, Jørgensen T, Andreasen AH, Broda G, Palmieri L, Giampaoli S, Don Franscesco C, Kee F, Ferrario MM, Kuulasmaa K, Saarela O, Sans S, Olsen MH. The prognostic shift from diastolic to systolic blood pressure in the MORGAM Project. J Hypertens. 2011: Abstract 1234 (oral)
118. Kruger R, Schutte R, Huisman HW, Hindersson P, Olsen MH, Eugen-Olsen J, Schutte AE. NT-proBNP, C-reactive protein and soluble uPAR in a bi-ethnic male population: the SAfrEIC study. 23rd European Society of Hypertension (ESH) meeting, Milan, Italy, June 14-17, 2013.
119. Kruger R; Rasmussen LM; Argraves WS; Eugen-Olsen J; Nielsen OW; Blyme A; Willenheimer R; Wachtell K; Olsen MH. Fibulin-1, a new marker of cardiac fibrosis, is closely related to N-terminal pro B-type natriuretic peptide in patients with mild to moderate aortic valve stenosis. 23rd European Society of Hypertension (ESH) meeting, Milan, Italy, June 14-17, 2013.
120. Blyme A, Asferg C, Nielsen O, Olsen MH, Wachtell K. HsCRP as a prognostic marker in patients with mild to moderate aortic valve stenosis. Danish Society of Hypertension annual meeting, Denmark, April 19-20, 2013
121. Greve SV, Blicher MK, Blyme A, Sehestedt T, Hansen TW, Rasmussen S, Vishram J, Ibsen H, Torp-Pedersen C, Olsen MH. Interaction of Hyperalbuminuria, Artherosclerotic Plaques and Elevated Pulse Wave Velocity with Age and Risk Category in Apparently Healthy Subjects. 23rd European Society of Hypertension (ESH) meeting, Milan, Italy, June 14-17, 2013. (oral)
122. Blicher MK, Greve SV, Brylski TO, Wachtell K, Ibsen H, Olsen MH. During antihypertensive treatment insulin sensitivity is not associated to brachial artery or forearm vasodilatory capacity in longstanding hypertension - A LIFE substudy. 23rd European Society of Hypertension (ESH) meeting, Milan, Italy, June 14-17, 2013. (oral)
123. Hvidt KN, Holm J-C, Olsen MH, Ibsen H. Obese children and adolescents have increased systolic and diastolic night blood pressure and night-to-day ratios. Journal of Hypertension Volume 31, e-Supplement A, June 2013, e35, 3B.07. European Society of Hypertension’s Annual Scientific Meeting, Milan, Italy, June 14-17 2013. (oral)
124. Hvidt KN, Olsen MH, Holm J-C, Olsen MH, Ibsen H. Impact of weight-reduction on arterial stiffness in obese children and adolescents: a one year follow-up study. Abstract Id: 0093. Artery Society’s annual meeting, Artery 13, London, UK, October 17-19 2013. Guided poster.
125. Hvidt KN, Holm J-C, Olsen MH, Ibsen H. Central Arterial Stiffness in Obese Children and Adolescents. Journal of Clinical Hypertension 2013;15 Suppl 1 :131. (poster)
126. Vishram JKK, Borglykke A, Andreasen AH, Jeppesen J, Ibsen H, Jørgensen T, Broda G, Palmieri L, Giampaoli S, Donfrancesco C, Kee F, Mancia G, Cesana G, Kuulasmaa K, Salomaa V, Sans S, Ferrieres J, Tamosiunas A, Söderberg S, McElduff P, Arveiler D, Pajak A, Olsen MH, On behalf of the MORGAM Project “Impact of age and gender on the prevalence of the metabolic syndrome and its components and risk of cardiovascular morbidity and mortality in Europeans. The MORGAM Project”. Journal of Hypertension Volume 32, Suppl.1. Poster at the Joint Meeting European Society of Hypertension – International Society of Hypertension, Athens, Greece, June 13-16, 2014.
127. Pareek M, Nielsen ML, Leósdóttir M, Kruger R, Greve SV, Blicher MK, Sehestedt T, Wachtell K, Nilsson PM, Olsen MH. Increased left ventricular mass reduces left ventricular diastolic function more in healthy subjects with elevated fasting glucose levels: a cross-sectional study. European Heart Journal Volume 25, Suppl.1. Poster presentation at the European Society of Cardiology Congress, Barcelona, Spain.
128. Pareek M, Nielsen ML, Leósdóttir M, Kruger R, Greve SV, Blicher MK, Sehestedt T, Wachtell K, Nilsson PM, Olsen MH. The Association of Diastolic Dysfunction with Left Ventricular Mass Index According to Glucometabolic Status: A Cross-Sectional Study. Journal of Hypertension Volume 32, Suppl.1. Oral presentation at the Joint Meeting European Society of Hypertension – International Society of Hypertension, Athens, Greece.
129. Pareek M, Nielsen ML, Leósdóttir M, Kruger R, Greve SV, Blicher MK, Hindersson P, Sehestedt T, Wachtell K, Nilsson PM, Olsen MH. Possible Mechanisms Explaining the Development of Left Ventricular Diastolic Dysfunction in Patients with Impaired Glucose Metabolism: A Cross-Sectional Study. Journal of Hypertension Volume 32, Suppl.1. Poster presentation at the Danish Hypertension Society Annual Meeting, Korsør. Poster presentation at the Joint Meeting European Society of Hypertension – International Society of Hypertension, Athens, Greece.
130. Pareek M, Nielsen ML, Leósdóttir M, Kruger R, Greve SV, Blicher MK, Rujic D, Hindersson P, Sehestedt T, Wachtell K, Nilsson PM, Olsen MH. Possible Determinants of Left Ventricular Mass Index and Their Association with Glucometabolic Status: A Cross-Sectional Study. Journal of Hypertension Volume 32, Suppl.1. Poster presentation at the Rising Stars Diabetes Conference, Novo Nordisk Scandinavia AB and Aarhus University, Aarhus. Poster presentation at the Joint Meeting European Society of Hypertension – International Society of Hypertension, Athens, Greece.
131. Nielsen ML, Pareek M, Greve SV, Diederichsen SZ, Kruger R, Blicher MK, Sørensen MH, Diederichsen AC, Olsen MH. The Association of Uncontrolled Hypertension with Coronary Artery Calcium Score, Left Ventricular Hypertrophy, and Left Ventricular Strain. Journal of Hypertension Volume 32, Suppl.1. Poster presentation at the Danish Hypertension Society Annual Meeting, Korsør. Poster presentation at the Joint Meeting European Society of Hypertension – International Society of Hypertension (Hypertension 2014), Athens, Greece.
132. Nielsen ML, Pareek M, Leósdóttir M, Kruger R, Greve SV, Blicher MK, Hindersson P, Sehestedt T, Wachtell K, Nilsson PM, Olsen MH. Association of Plasma Levels of Glucose and Growth Differentiation Factor 15 (GDF-15): A Cross-Sectional Study in The Malmö Preventive Project Re-Examination Study Cohort. Journal of Hypertension Volume 32, Suppl.1. Poster presentation at the Rising Stars Diabetes Conference, Novo Nordisk Scandinavia AB and Aarhus University, Aarhus. Poster presentation at the Joint Meeting European Society of Hypertension – International Society of Hypertension (Hypertension 2014), Athens, Greece.
133. Blicher MK, Greve SV, Kruger R, Pareek M, Sehestedt T, Vishram JKK, Jørgensen T, Olsen MH. Prognostisk importance of vascular age estimated from pulse wave velocity. Oral presentation at the Joint Meeting European Society of Hypertension – International Society of Hypertension (Hypertension 2014), Athens, Greece.
134. Greve SV, Blicher MK, Kruger R, Pareek M, Sehestedt T, Vishram JKK, Jørgensen T, Olsen MH. Hyperglucemia and dyslipidemia is associated with elevated vascular age estimated from pulse wave velocity. Poster presentation at the Joint Meeting European Society of Hypertension – International Society of Hypertension (Hypertension 2014), Athens, Greece.

Undervisningsportfolio

1. Formel pædagogisk uddannelse
1) Forsvarets pædagogiske kursus 1992 (5 dage)
2) Aztecc kommunikationskursus, Aztra Zenica, 2002-03 (3 x 2,5 dage)
3) Rigshospitalets vejlederkursus 2007 (2-3 dage)

2. Uddannelsesadministrative opgaver
1) Bedømmelse af Ph.d. opgaver
2009: Bedømmer af Michael Præstholms Ph.d.-opgave ved Århus universitet: “Essential hypertension: vascular and diagnostic aspects with potential influence on patient management” forsvaret 4. december 2009.
2011: Bedømmer af Skjalg Hassellunds Ph.d.-opgave ved Oslo Universitet: “Effects of Anthocyanin Supplementation on Pathophysiological Markers of Cardiovascular Disease”
2012: Bedømmer af Morten Engholm Pedersens Ph.d.-opgave ved Århus Universitet: Vascular Remodelling in Hypertension – Basic and Clinical Aspects” forsvaret 26. oktober 2012.
2012: Bedømmer af Sofia Enhörnings Ph.d.-opgave ved Lunds Universitet: ”The vasopressin system in diabetes, obesity and the metabolic syndrome” forsvaret 14. december 2012.
2013: Formand for bedømmelsesudvalget for Lotte Saabys Ph.d.-opgave ved Syddansk Universitet: “The consequences of the universal 2007 DEFinition of Acute Myocardial Infarction studied prospectively in a Danish consecutive hospital population (DEF-AMI)” forsvaret 3. december 2013.
2014: Formand for bedømmelsesudvalget for Jane Angel Simonsens Ph.d.-opgave ved Syddansk Universitet: “Prognostisk og prædiktiv værdi af myokardiescintigrafi hos patienter med kronisk iskæmisk hjertesygdom” forsvaret 20. marts 2014.
2) Ledelsesmæssige opgaver
2006-12: Bestyrelsesmedlem i Dansk Hypertensions Selskab
2007-18: Council member of European Society of Hypertension
2009-: Medlem af Dansk Cardiologisk Selskabs arbejdsgruppe vedr. Præventiv Kardiologi og Rehabilitering
2010-: Opbygning, koordinering og ledelse af European Society of Hypertensions (ESH) E-learning program til opdatering og reakkreditering af ESH hypertensionsspecialister
2012-: Formand for Forskeruddannelsesprogrammet (FUP) for Hjerte, Nyre og Kredsløb ved Syddansk Universitet
2014-: Council member of European Society of Cardiology Council on Hypertension.

3. Erfaring med undervisning (inklusiv udvalgte eksempler)
1) Prægraduat undervisning af medicinstuderende (7. semester og K14) (2008-)
2) Postgraduat undervisning af
Læger ved nationale møder og internationale kongresser (1998-)
- 2009: Subklinisk kardiovaskulær skade. Patofysiologiske – kliniske - behandlingsmæssige aspekter. DHS Årsmøde i Christiansminde (Arrangør).
- 2013: Workshop in Artery Disease. From basic biological research, through better pathophysiological understanding, to improved (individualized) prevention and treatment. OUH (Arrangør)
- 2013: Symposium in honour of Stéphane Laurent. Different aspects of large artery disease. OUH (Arrangør)
Praktiserende læger (medicinalindustrisponsorerede møder) (2003-)
- 2013: Optimeret Diabetes Behandling - Hypoglykæmi og Hypertension. Indlæg om hypertensions-behandling. Esbjerg (Arrangør).
Ph.d. studerende (nationale og internationale ph.d. kurser) (2003-)
- 2009: Hypertension and cardiovascular (CV) ageing – Bridging basic research
and clinical science. Nordisk ph.d. internatkursus sponsoreret af The joint Committee of the Nordic Medical Research Councils (NOS-M) og DaCRA (Arrangør og leder)
- 2010: Hypertension and Cardiovascular Disease - Bridging basic research, clinical science and daily practice. The Second Nordic University Research Course, Oslo. Nordisk ph.d. internatkursus sponsoreret af DaCRA (Arrangør og kursusleder)
- 2012: The Third Nordic University Research Course, Ystad/Malmö (Medarrangør).
- 2012: Hypertension and target organ damage – how to do, OUH (Arrangør og leder).
- 2014: Nordisk Ph.d. internatkursus ved SDU: “Artery disease – From basic biological research through better understanding to improved prevention and treatment”. Nyborg (Arrangør og kursusleder).
Yngre læger i afdelingen (daglig klinik og kurser) (2008-)
3) Undervisning af andre faggrupper
Medicinal-repræsentanter (halvdags kurser) (2002-2008)
Farmaceuter (halvdags kurser) (2007)
Sygeplejersker i afdelingen (daglig klinik, temamøder og videreuddannelse) (2008-)

4. Erfaring med vejledning
2003-07: Ph.d.-medvejleder for Marina K. Christensen, ”Kollagen markørers relation til det kardiovaskulære system”, Klinisk Fysiologisk og Nuklear Medicinsk afdeling, KAS Glostrup. Forsvaret og erhvervet september 2007.
2006: Klinisk vejleder for læger i introduktionsstilling og hoveduddannelse i kardiologi, Kardiologisk afd. B, Hjertecentret, Rigshospitalet
2007-11: Ph.d.-medvejleder for Camilla Lund Søraas, ”Den prognostiske betydning af venstre ventrikel hypertrofi efter koronar revaskularisering”, Kardiologisk Afdeling, Ullevaal Universitets Hospital, Oslo med Sverre E. Kjeldsen som hovedvejleder. Indleveret 2012.
2008-11: Ph.d.-hovedvejleder for Thomas Sehestedt, ”Betydningen af subklinisk kardiovaskulær skade og nye risikomarkører for risikostratificering specielt hos personer med højt normalt blodtryk”, Medicinsk Afd. M, Glostrup Hospital. Forsvaret og erhvervet 5/2 2011.
2008-13: Ph.d.-medvejleder for Stig Lyngbæk, ”SuPAR – en ny markør for udvikling af kardiovaskulær sygdom”, Medicinsk Afd. M, Glostrup Hospital med overlæge Jørgen Jeppesen som hovedvejleder. Forsvaret og erhvervet januar 2013.
2009-14: Ph.d.-hovedvejleder for Julie Vishram, ”Det metaboliske syndroms prognostiske berettigelse og den prognostiske betydning af systolisk versus diastolisk blodtryk ved stigende alder”. Medicinsk Afd. M, Glostrup Hospital og Forskningscenter for Forebyggelse og Sundhed. Forsvaret og erhvervet maj 2014.
2010-14: Ph.d.-medvejleder for Kristian Hvidt, ”Blodtryk og central karstivhed hos adipøse børn. Relationer til det metaboliske syndrom og subklinisk kardiovaskulær skade. Effekt af vægtreduktion”. Kardiologisk Afsnit, Medicinsk Afdeling, Holbæk Sygehus.
2011-: Ph.d.-hovedvejleder for Adam Blyme, “Markers of Left ventricular Hypertrophy - A Study in Patients with Aortic Valve Stenosis and in the General Population”. Medicinsk Afd. M, Glostrup Hospital. Indregistreret per 1/9 2011.
2011: Hovedvejleder for Henrik Steglich-Arnholm OSVAL II opgave: ”Betydningen af overvægt på den prognostske betydning af N-terminal pro brain nitriuretisk peptid, og andre markører, umiddelbart raske personer”. Medicinsk Afdeling M, Glosrup Hospital. Bestået med 12.
2012-: Ph.d.-medvejleder for Britta Frederiksen-Møller, ”SYDHOP – SYDdansk Hypertension og Oedem i Præeklampsi studium Sygehus Fyn” Gynækologisk/obstetrisk Afd. D, OUH. Indregistreret 2011.
2012: Hovedvejleder for Thomas Sehested OSVAL II opgave: “Simple cardiovascular risk stratification tools and anthropometric measures. The MORGAM project”. Medicinsk Afdeling M, Glosrup Hospital. Bestået med 12.
2012-13: Medvejleder for Kasper Bostlund Assersen, Etårig, prægraduat forsker-uddannelse med projektet: ”Mekanismer bag forhøjet blodtryk: Lokal gennemstrømning i nyrerne ved hypertension” Nuklearmedicinsk Afdeling, OUH.
2012-: Ph.d.-hovedvejleder for Sara Vikström, ”Subklinisk organskade – markører for den enkelte persons følsomhed for den skadelige virkning af risiko faktorer (specielt forhøjet blodtryk og øget alder)” Endokrinologisk Afd. M, OUH. Indregistreret marts 2012. 2012-: Ph.d.-medvejleder for Mette Hjortdal Sørensen, ” Biomarkører og koronar kalk. Inflammatoriske- og calcium-fosfatmetaboliske markørers relation til kalk i koronarkarrene” Kardiologisk Afd. B, OUH. Indregistreret maj 2012.
2012-: Ph.d.-medvejleder for Jacob Volmer Stidsen, ”Individually tailored treatment in T2D” Endokrinologisk Afd. M, OUH. Indregistreret 2012.
2012-: Ph.d.-hovedvejleder for Marie K. Blicher, ”Kateterbaseret renal denervering hos patienter med behandlingsresistent essentiel hypertension – Effekt på nyre, kar og insulin følsomhed” Endokrinologisk Afd. M, OUH. Indregistreret september 2012.
2014-: Ph.d.-hovedvejleder for Manan Pareek, “Detection of Early Atherosclerosis and Arteriosclerosis using Biomarkers and PET/CT (DETECT) in Healthy Controls and Patients with Hypertension, Type 2 Diabetes, or Carotid Artery Stenosis”.
2014-: Ph.d.-hovedvejleder for Thomas Bastholm Olesen, “HOMA Index based Phenotyping in Type 2 Diabetes – Cardiovascular Characteristics – An ITT Substudy” (HOMAP-CV). Endokrinologisk Afd. M, OUH
2014: Hovedvejleder for Søren Diederichsen OSVAL II opgave: “ECG pattern of left ventricular hypertrophy or ST-segment deviation in a healthy population: The impact of fasting glucose and other cardiovascular risk factors”. Endocrinologisk Afdeling M, OUH. Bestået med 12.
2014-: Ph.d.-medvejleder for Monija Mrgan, “Coronary plaque morphology and plaque progression in patients with newly diagnosed type-2 diabetes mellitus”. Kardiologisk Afd., Sydvestjysk Sygehus, Esbjerg
2014-: Post doc vejleder for Trine K. Sønder, Endothelial (dys)function in patients with type 2 diabetes (EDF-T2D). Endokrinologisk Afd. M, OUH
2015-: Ph.d.-hovedvejleder for Mette Lundgren Nielsen, “HOMA Index – As Prognostic Marker in a General Population and as Marker of Metabolic Phenotype in Type 2 Diabetes - An ITT Substudy (HOMAP-Metabolic). Endokrinologisk Afd. M, OUH

5. Erfaring med eksamen
Lavet og rettet skriftlige opgaver til OSCE eksamen (2010-)

6. Materialer
1) Guest editor in Archives of Medical Science I 2008: “Special issue on hypertension”
2) Ansvarlig for udformning og opdatering af European Society of Hypertensions ”Distance learning project”, som ESH hypertensions specialister har adgang til via ESHs hjemmeside
3) Co-editor på en ny bog, der udkommer i 2015: “Early Vascular Ageing (EVA) - new directions in cardiovascular protection”

7. Uddannelsesudvikling og universitetspædagogisk (følge)forskning, herunder pædagogiske priser
Ifølge mit pædagogiske læringssyn er det en basal udfordring ved den lægevidenskabelige uddannelse at opretholde balancen mellem
- At give de studerende en tværfaglig, problemorienteret undervisning uden at de studerende mister det brede faglige fundament.
- At give de studerende det brede faglige fundament uden at undervisningen bliver for katedral og uden at indholdet bliver kedelig udenadslære.
- At give de studerende et indblik i lægens dagligdag tidligt i studiet uden at spilde studenternes/lægernes tid i klinikken pga. manglende faglig viden til at forstå observationerne.
Jeg mener, at løsningen er en passende balance med et kort, tidligt klinikophold efterfulgt af en bred faglig undervisning, som bør være overvejende katedral undervisning jævnligt kombineret med interaktiv klasseundervisning, som i tiltalende grad i løbet af studiet kan krydres med tværfaglig, problemorienteret undervisning, som på 2. del af studiet kan blive mere klinisk orienteret.
Endvidere bør man udnytte og styrke den tætte forbindelse mellem SDU og OUH, således at medicinstudiet gradvist bliver mere klinisk uden helt at tabe forankringen i SDU. Derved vil de medicinstuderende tidligt erkende den kliniske relevans af deres teoretiske undervisning, hvilket øger motivationen og derigennem indlæring. Samtidigt vil de næsten færdiguddannede medicinstuderende bevare kontakten til SDU og basalforskningen, hvilket vil fremme tilknytningen til SDU, når de er færdige, og derved styrke samarbejdet mellem SDU og OUH yderligere og fremme senere tværgående/translationel forskning.
Generelt mener jeg, at studerende skal engageres i undervisningen for derved bedre at kunne huske stoffet. Dette gøres bedst, hvis de studerende pålægges forberedelse mhp. kort egen fremlæggelse, som derefter kan benyttes som udgangspunkt for den egentlige undervisning, der igen kan føre til en fornyet hjemmeopgave til næste gang.

8. Refleksion over egen pædagogisk praksis og fremtidig udvikling - herunder undervisningsevalueringer (kun til internt brug)
Jeg mener, at min rolle fremadrettet fortsat skal være fokuseret på postgraduat lægeuddannelse specielt i form af Ph.d. kurser, hvor min ekspertise vil blive bedst udnyttet. Det er dog stadig relevant, at jeg varetager hypertensions-undervisningen under K14, idet de studerende herved lære mig at kende, hvis de senere har kliniske eller forskningsmæssige spørgsmål relateret til hypertension.